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Chapter 1. Malaria and Project Background 
1.2. Life cycle of the malaria parasite 
The hematophagous anthropophilous female Anopheles mosquito is the vector through 
which the malaria parasite is transmitted to humans. Out of approximately 300 species of 
the Anopheles genus, 85 are malaria vectors. Only the female Anopheles is 
hematophagous, and possesses mandibles and maxillae for this purpose, as it is 
necessary for the female to have a blood meal before reproduction [Dutta and Dutt, 1978]. 
Humans are the intermediate hosts, in which the asexual reproductive stage of the 
parasite life cycle takes place [Moore et al., 2002]. The sexual reproductive stage occurs 
within the midgut of the mosquito [Frederich et al. 2002] (Figure 1.1.1.). 
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life cycle occurs within the Anopheles mn<:m 
on a human host with erythrocytic ::>LdIY" 
It is initiated when the 
Gametocytes are 
within the 
encysts In the gut wall and 
ingested and develop into male microgametes and female m~'r:rI"ln"mAI(lr.vtA 
mosquito's gut. Fertilization occurs, after which the zygote 
forms an DCySt which are upon rupture and 
mig to salivary for rr"n<:''n;""i,m to a vArtAh host (in this case a human) 
during the mosquito's blood [Dutta and 1978], 
J,;::,;::,I'\§<))(ll<:lI(Schizogonic) phase 
This can further divided into an exoerythrocytic or phase and an 
erythrocytic phase [Fn!;derich et ai, 2002], The exoerythrocytic phase is initiated with the 
of sporozoites from an infected mosquito into a human, The sporozoites 
to liver they into of schizont and 
development is dependent on Plasmodium P, vivax ovale form 
hypnozoiles, which may remain dormant in the liver for <:AIJAr,,1 years, before developing 
into schizonts, fa/ciparum and malariae do not form hypnozoites and development of 
schizonts takes approximately 1 to 2 weeks [Frederich et ar, 2002] Merozoites are 
upon rupture the initiating the erythrocytic 
the n:> ,:>,,"" life invasion of the eryth IS and 
involves and erythrocytic receptor [Chitnis and 2000]. 
Within the undergo ""C;Au,a, reproduction, forming rings and 
trophozoites, and finally erythrocytic schizonts, Lysis of the erythrocyte at this 
releases merozoites that either invade new blood or differentiate into 
gametocytes, Continuation of the erythrocytic phase is by rupturing of 
intFlr.IF,rl erythrocytes the short time period (30 seconds) of erythrocytic , which 
overwhelms the immune system [Frederich , 2002], are transmitted to a 
Anopheles mosquito during completing the [Frederich et ar, 
2002], The whole erythrocytic cycle 48 hours tropical (P falciparum) and tertian 











Chapter 1. Malaria and Project Background 
fever occur upon rupture of infected erythrocytes, due to the release of plasmodial waste 
products and other foreign substances into the blood stream [Dutta and Dutt, 1978]. 
1.3. Distribution 
Malaria is found in tropical and subtropical areas throughout the world, where the 
temperature is above 16°C - the minimum temperature at which development of the 
malaria parasite occurs [Sachs and Malaney, 2002] (Figure 1.3.1.). The most widely 
affected area is Sub-Saharan Africa. 
Malaria, 2003 
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Figure 1.3.1.: Global distribution of malaria [www.who.intiith/chapterOS_m08_malaria.htmlj. 
Malaria in South Africa is found mainly in the northern regions of low altitude, such as 
Mpumalanga, Northern Province and northeastern KwaZulu-Natal 
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As already mentioned, Sub-saharan Africa is the largest area to be affected with malaria 
and has the vast majority of malaria-related deaths. The reason for this is due to several 
reasons such as climate [Outta and Outt, 1978; www.who.inUinf-
fs/en/1InformationSheet03.pdf], vector species [Winstanley, 2001], flora and fauna, land-
use, resources and infrastructure as well as rapidly developing resistance to first-line drugs 
and insecticides. The impact and factors influencing the spread of malaria, with special 
reference to Africa, will be discussed in the following section. 
1.4. The impact of malaria 
The devastating effects of malaria are especially noticeable in countries or regions with 
high infection rates, such as sub-Saharan Africa. It is estimated that malaria is responsible 
for 2000 deaths dally (mostly children) worldwide, 90% of these being in Africa. The 
disease places a huge burden on the underdeveloped health care systems and available 
resources in these countries, and many eradication campaigns have failed due to lack of 
funding and infrastructure [www.who.inUinf-fs/en/1InformationSheet03.pdf]. 
Malaria has a great impact on social and economic development, as seen in the global 
distribution of per-capita gross domestic product (GOP), which is lowest in malaria-infected 
countries. The economic growth is also substantially less in these areas. The explanations 
for the correlation between malaria and poverty are numerous. Malaria influences 
development by affectin9 fertility, mortality, population growth, productivity, absenteeism, 
underdevelopment of children, fetal development, investments and medical costs. Lack of 
both personal and government funds to spend on malaria prevention and cure aids 
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1.5. Factors influencing the spread of malaria 
There are many factors that affect the spread of malaria, These can be divided up into two 
broad groups, namely; i) social and environmental factors and ii) resistance of both the 
mosquitoes to insecticides and the parasites to chemoprophylactics. 
1.5.1. Social and environmental factors 
Social factors such as war, population growth, tourism and HIV infection [Rowland-Jones 
and Lohman, 2002] have led to a resurgence of the disease, by increasing the number of 
susceptible individuals and communities [Greenwood and Mutabingwa, 2002] and by 
decreasing very limited funding that would previously have been used for malaria 
prevention and control. 
Environmental changes and ecological disturbances also have a profound effect on the 
resurgence of malaria. Both these phenomena shift the ecological balance and therefore 
affect the population growth of host, vector and parasite. Examples of disturbances caused 
by man are deforestation, land use changes and building of dams and other water control 
projects. Human movement also plays a role as it increases the number of migrants who 
would not normally be exposed to malaria and therefore have no innate immunity or 
knowledge of ways to minimize infection. Environmental factors, such as climate, 
temperature, rainfall and EI Nino also influence the spread of the disease, by making 
areas, which are non-e demic, suitable for vector growth and thus parasite transmission 
[Patz et al., 2000]. 
1.5.2. Resistance 
The failure of vector control programs and developing resistance of mosquitoes to 
insecticides places increasing reliance on antimalarial chemotherapy. Today 
chemotherapy is the biggest weapon in the fight against malaria, although resistance to 
virtually all antimalarials has been noted [Campbell, 1997]. Resistance is defined as the 











absorption of a drug given in doses equal to, or higher than, those usually recommended 
but within the limits of tolerance of the subject" [WHO, 1973]. Chloroquine-resistant 
fa/ciparum malaria was first noted in Southeast Asia and South America in the early 
1960's. By the late 1980's resistance to sulfadoxine-pyrimethamine and to mefloquine was 
also reported [Oaks et ai , 1991; Wongsrichanalai at al. , 2002] . There are effective drugs 
available , such as artem isinin and its derivatives, but these are very expensive and are 
therefore not viab le options for developing countries [Wongsrichanalai et al., 2002]. 
Many factors contribute to the development and spread of resistance. Selection and 
spread of resistant parasites occurs under drug pressure and non-compliance, such as 
under-dosage or treatment not being completed. Characteristics of the drug are also 
important factors in the development of resistance. Drugs with long half-lives, such as 
mefloquine, may select for resistant strains as they will be present in the body at sub-
therapeutic levels after treatment andlor cure of an infection. Recrudescence at this stage 
will select for resistant parasites . Widespread, intense usage of drugs can also increase 
drug selection pressure, thereby favoring resistant strain development [Wongsrichanalai et 
a/., 2002] . 
1.6. Preventative measures 
1.6.1 . Vector control 
Vector control after World War II consisted of draining mosquito breeding grounds (i.e. 
stagnant water such as swamps) , screens and spraying with DDT. In 1955, the Eighth 
World Health Assembly launched a plan , the objective of which was worldwide eradication 
of malaria. This plan was successful in many countries such as Greece, Venezuela and 
the USA. Unfortunately malaria eradication was not achieved in Africa, due to poor project 
planning, infrastructure and developing resistance to insecticides [McMillan and Meltzer, 
1996]. Owing to these failures, the plan for eradication of malaria through vector control 
was abandoned in the 1960s [Guerin et al., 2002]. This meant withdrawal of international 
funding , and resulted in devastating consequences for deve loping countries, which do not 












this period was strictly controlled owing to its impact on the environment [Oaks et a/., 1991] 
and fear of further resistance development. Insecticide-treated nets now playa vital role in , 
vector control, although their effectiveness is debatable [McMillan and Meltzer, 1996]. 
Malaria control is at present mainly reliant on chemoprophylaxis, due to failure of vector 
control strategies and other eradication campaigns . 
1.6.2. Drug Therapy 
Antimalaria l drugs can be divided into two types, blood schizontocides, which target the 
erythrocytic stage of the parasite and tissue schizontocides, which target the liver stage of 
the parasite [Kumar et a/., 2003]. Unlike other forms of malaria, fa/ciparum malaria does 
not form hypnozoites, which can remain dormant and cause reinfection at a later stage. A 
single blood schizontocide is therefore sufficient as treatment for fa/ciparum malaria 
[Kumar et aI. , 2003] and these drugs will therefore be focused on. 
There are three main groups of commonly prescribed antimalarials wh ich are listed below; 
Antifolates 
Quinolines 
Artemisinin and derivatives 
1.6.2.1. Antifolates 
Antifolate antimalarials act by inhibiting the dihydrofolate pathway of the parasite . This 
inhibits folate synthesis , which results in decreased pyrimidine synthesis and ultimately 
inhibition of DNA synthesis and decreased methionine and serine synthesis, leading to 
parasite death . There are 2 classes of antifolate antimalarials, inhibitors of dihydrofolate 
reductase (DHFR) and inh ibitors of dihydropteroate synthetase (DHPS) [Casteel, 1997; 
Foote and Cowman, 1994]. 
DHFR inhibitors 
DHFR exists as a bifunctional enzyme in protozoa and reduces the dihydrofolate (DHF) 
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synthesis and salvage pathways. DHFR inhibitors, pyrimethamine and cycloguanil 
selectively inhibit P. fa/ciparum DHFR (due to structural and functional differences between 
P. fa/ciparum and human DHFR), thereby disabling the reduction of DHF and therefore 
tetrahydrofuran (THF) formation, an essential cofactor in a number of vital reactions, such 
as synthesis of certain amino acids and purine nucleotides [Oliiaro, 2001; Yuthavong, 
2002]. DHFR inhibitors mimic the pteridine ring of DHF and compete with it for the active 
site of DHFR. The compound fits into the hydrophobic active site and is stabilized via 
hydrogen bonding with Asp54 and hydrophobic interactions with residues 108, 16, 51, 59 
and 164. DHF is a flexible molecule due to its bridging alkyl chain (Figure 1.6.2 . .1 .1.), which 
allows the amino benzyl glutamate portion of the molecule to be perpendicular to the 
pteridine ring, when it is bound by DHFR. This is unlike DHFR inhibitors, which tend to be 
rigid and it has been proposed that this rigidity may playa role in resistance [Olliaro, 2001; 
Warhurst 1998]. 
° lO'H 
° ~~ CO,H 
)~N'Y'NJJ 
A)l ) t H DHF 
H2N N ~ (natural substrate) 
pleridine ring amino benzoyl glutamate 
bridging alkyl chain 
Proguanil (biguanide derivative) 
H,N 
~N 





H,N N NH , 
Cycloguanil 
Figure 1.6.2.1.1.: Structure of DHF and DHFR inhibitors pyrimethamine, cycloguanil, 
proguanil [Casteel, 1997; Frederich et al., 2002]. 
Proguanil is believed to be a prodrug of cycloguanil, and is converted to its active form by 
cytochrome P450. The efficacy of cycloguanil/proguanil is therefore affected by genetic 











(2003), suggests that the antimalarial action of proguanil is not solely responsible for the 
antifolate action of the cycloguanil. They suggest that proguanil, a biguanide derivativ~, 
binds to endogenous metals forming a complex with inhibitory falcipain-2 activity. 
Falcipain-2 'is a, cysteine protease involved in haemoglobin degradation' [Shenai et - aI., 
2000], which is necessary for parasitic protein synthesis [Banerjee and Goldberg, 2Q01]. 
Cysteine protease inhibitors completely prevent haemoglobin' degradation, preventing 
protein synthesis and hence parasite growth [Rosenthal et aI., 1993; Shenai and 
Rosenthal, 2002]. 
Structure Activity Relationships 
Molecular modeling is being used to mimic the active site of DHFR and allows predictions 
of essential characteristics, as seen in Figure 1.6.2.1.2., needed in inhibitors for optimum 
binding and hence efficacy [Warhurst, 1998]. 
"'bonds .;:nh AspS<!, aN'cettd' by 
ASn5llJ~, qs!59AYgon I\lIfne. 'helix 
ExCluiled v~rume 
Arorru,o!lc, lIY,4Jrophoblc 
, , ~tiYilrophoble ' 
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DHPS inhibitors 
DHPS is also a bifunctional enzyme in protozoa and combines p-amino benzoic acid 
(PABA) with a pterin derivative to form dihydropteroate. Inhibitors are highly selective for 
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Figure 1.6.2. 1.3.: Structure of p-aminobenzoic acid (PABA) [Clayden et al., 2001], a 
sulphone [Bruce-Chwatt et aI., 1981] and various sulphonamides [Casteel, 1997]. 
Resistance to antifolates 
Resistance is widespread and limits the use of this drug class. Resistance can be 
attributed to point mutations in the DHFR and DHPS genes as shown in Figure 1.6.2.1.4. 
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Figure 1.6.2.1.4.: Targets of and mutations conferring resistance to DHFR and DHPS 
inhibitors [Olliaro, 2001]. 
1.6.2.2. Quinoline-containing antimalarials 
Quinoline-containing antimalarials (Figure 1.6.2.2.1.) can be split into 2 subclasses: 
4-aminoquinolines 
Aryl-amino alcohols 
Both subclasses act on the parasite's endolysosomal system, differing in their interaction 
with their putative targets [Warhurst, 1987] and have inversely related parasite sensitivities 
[Fitch, 2004; Olliaro, 2001]. The 4-aminoquinoline subclass includes chloroquine (CQ), 
amodiaquine and pyronaridine. These compounds are all weak bases and are 
diprotonated and hydrophilic at neutral pH. The aryl-amino alcohol subclass consists of 
quinine, quinidine, mefloquine and halofantrine. These compounds are weaker baSes than 





















Figure 1.6.2.2.1.: Structures of various 4-aminoquinoline and aryl-amino alcohol 
antimalarials. 
Background 
Quinine, a component of the Cinchona bark, was the first antimalarial to be discovered and 
was used by South American Indians as a treatment for malaria fevers [Oaks et aI., 1991]. 
Chemical modification of quinine, in order to develop less toxic derivatives, led to the 
synthesis of the 4-aminoquinoline, chloroquine [Loeb et al., 1946]. Investigation into the 
structure-activity relationship of various 4-aminoquinolines lead to the synthesis of 
amodiaquine [O'Neill et aI., 1998]. Development of resistance to the 4-aminoquinolines 
prompted the development of the aryl-amino alcohols, mefJoquine and halofantrine 
[Casteel, 1997; Foley and Tilley, 1997]. 
Mechanism of action 
Quinine-containing antimalarials act on the mature (Le. trophozoite) stages of the asexual 
blood phase of the parasite's life cycle. In this phase, parasites degrade haemoglobin, 











Chapter; MalaCIa an(i PrOject Background 
used to synthesize proteins. This is necessary as intraerythrocytic stages of P. fatciparum 
are able to synthesize very few amino acids de novo [Sherman, 1977]. Haemoglobin 
degradation occurs in excess of the amount needed for sufficient amino acid production 
This excess degradation serves to reduce the colloid-osmotic pressure within the host cell, 
thereby maintaining the osmotic stability of the infected erythrocyte [Lew et at., 2004]. 
Haemoglobin degradation is thought to be an ordered event involving a number of classes 
of enzymes. Plasmepsins I, II and IV (aspartic proteases and histo-aspartic protease) 
[Banerjee et at., 2002] initiate haemoglobin hydrolysis, and produce denatured 
haemoglobin which is then cleaved into small peptides by falcipains -2 and -3 (cysteine 
proteases) [Shenai et at., 2000; Sijwali et at., 2001] and falcilysin (metalioprotease) 
[Banerjee and Goldberg, 2001; Gluzman et at., 1994; Kolakovich Eggleson et at., 1999]. 
These small peptides are then transported to the parasite cytoplasm where they are 
hydrolyzed into amino acids [Kolakovich et at., 1997]. Ferriprotoporphyrin IX (FP) is a toxic 
byproduct of haemoglobin degradation, and is sequestered by the parasite in crystalline 
non-toxic structures called haemozoin [Cowman, 1995; Fitch, 2004; Foote and Cowman, 
1994]. 
There have been a number of theories regarding the mechanism of action of the 4-
aminoquinoline antimalarials, such as DNA interaction [Cohen and Yielding, 1965; O'Brien 
et at., 1966], inhibition of protein synthesis [Sirolia and Padmanaban, 1991], inhibition of 
vacuolar phospholipase [Ginsburg and Geary, 1987] and Iysosomotropism [De Duve et at., 
1974]. However, the most widely accepted hypothesis proposes that 4-aminoquinolines 
exert their specific antimalarial activity by interfering with haemozoin formation [Fitch, 
1986]. The quinoline methanols have been shown to have a related mechanism of action 
to the 4-aminoquinolines although the precise mechanism by which this occurs is still 
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Structure Activity Relationships 
4-Aminoquinolines 
The two most common examples of this subclass, CQ and amodiaquine, will be discussed. 
General: The aminoquinoline ring is responsible for complexing ferriprotoporphyrin IX 
(Fe(III)pPIX). It was shown that strong complexes of the compound and Fe(III)pPIX are 
only formed by the 2- and 4-aminoquinolines, possibly because only 2- and 4-
aminoquinolines possess unique resonance forms [Egan et aI., 2000]. The 4-arylamino 
moiety however, enhances the activity of derivatives against CQ resistant strains. 
Comparison of the pKa values of CQ and amodiaquine with other aminoquinolines, reveals 
that both these compounds possess relatively high pKa values. It has been suggested that 
the formation of Fe(III)pPIX-chloroquine complex involves cation-7t interactions, although 
complex formation is pH insensitive [Kaschula et al., 2002]. 
The removal of the CI group at the 7-position of the quinoline ring abolishes the 
antiplasmodial activity of the respective compounds. It is believed that the 7 -chloro group 
is required for the inhibition of ~-haematin formation [Egan et al., 2000]. Experiments 
where performed in which the 7-chloro group was replaced with various other sUbstituents. 
It was determined that lipophilicity, hydrophilicity or electronegativity at position 7 are not 
significant factors in the antimalarial activity [De et aI., 1998]. Other modifications on the 
quinoline ring, of 4-aminoquinolines, such as the oxidation of the nitrogen atom, results in 
compounds that display a high level of antiplasmodial activity [Elslager et al., 1964]. 
The basic amino side chain is thought to be necessary for accumulation of the drug in the 
food vacuole of the parasite [Egan et aI., 2000] and to assist binding to haem. 
Accumulation is thought to occur firstly via the weak base effect and then via pH trapping 
[O'Neill et aI., 1997]. 
The number of carbons between the two nitrogens in the diaminoalkane side chain also 
influences the activity of these compounds. It was found that side chains with 2-12 carbons 












fa/ciparum. Aminoquinolines with short (2-3 carbon) or long (10-12 carbon) diaminoalkane 
side chains however, were found to be active against CQ sensitive, resistant and multiply 
resistant P. fa/ciparum in vivo [De et aI., 1996; Ridley et a/., 1996]. Intermediate (tetra-, 
penta-, hexa- and octa-methylene) diaminoalkane side chains on the other hand, were 
active against CO sensitive and not CO resistant P. falciparum [De et al., 1998]. Bray et al. 
(1996), observed that dealkylation increases cross resistance and verapamil resistance 
reversal of the major metabolites of both CO and amodiaquine. They also proposed that 
compounds with a log D (lipid solubility) of 1.8-3 at a pH of 7.2 with a tertiary amino moiety 
0.6-0.9 nm from the ring nitrogen would have activity in the nanomolar range and display 
minimal cross resistance with CO. 
CQ: CO contains a 7 -chloroquinoline substituted ring and a diami e side chain [O'Neill et 
al., 1998]. It has been observed that short, 2 carbon side chain CO analogues have in vitro 
activity «15nM) against CO resistant strains but undergo N-terminal dealkylation in vivo, 
producing less active metabolites [Biagini et a/., 2003]. 
Figure 1.6.2.2.2. summarizes the structure-function relationship of chloroquine, although 
similar features confer the same properties in amodiaquine. 
Inhibition of Il-haematin 
formation 
Weak bases: assist 
i  drug accumulation 
via pH trapping 
Figure 1.6.2.2.2.: Structure-function relationship in CO [Egan et aI., 2000]. 
Amodiaquine: Amodiaquine is hepatotoxic and causes agranulocytosis. This is not 
surprising, as the amodiaquine side chain contains a 4-aminophenol, which undergoes 
metabolic oxidation to produce quinoneimines [O'Neill et aI., 1998]. This aromatic hydroxyl 
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Aryl-amino alcohols 
These compounds accumulate in the acidic food vacuole of the parasite due to pH 
trapping [Yayon et al., 1984]. Here the compounds are thought to complex to haem, and in 
so doing are toxic to the parasite. This complexation to haem is reliant on the quinoline 
ring. It has also been noted that amino alcohol antimalarials require an aromatic and amino 
moiety separated by 2-3 carbon atoms for activity [Bhattacharjee and Karle, 1996]. 
Resistance 
CO resistance was first noted in Southeast Asia and South America in the late 1950's, and 
led to many theories on the mechanisms of resistance [Batra and Bhaduri, 1997; Olliaro, 
2001; Thaitong et al., 1983; Warhurst, 1988]. One of the first developments into the 
mechanism of resistance to CO was the finding that resistant parasites accumulate 
significantly less CO than sensitive ones [Fitch 1970; Verdier et al., 1985]. This led to the 
assumption that resistance could be mediated through either increased efflux, decreased 
influx or a combination of both [Foote and Cowman, 1994; O'Neill et al., 1998]. Further 
research has shown this decrease in CO concentration to be a factor in resistance, 
although it is generally accepted that multiple gene mutations and mechanisms confer 
resistance. 
Decreased prophylactic concentration, cross-resistance between multiple structurally 
unrelated drugs and the observation that verapamil, as well as other structurally and 
chemically related compounds, could modulate P. falciparum resistance to CO (see 
section on resistance reversal) [Martin et al., 1987; Zamora et al., 1988]. led to the 
assumption that the cross resistance seen in P. falciparum is similar to that seen in 
multidrug resistant (MDR) cancer cells [Martin et al., 1987]. This led to the hypothesis that 
the resistance of P. falciparum may be due to similar mechanisms to those seen in cancer 
cells [Bray and Ward, 1998]. P-glycoproteins are membranous proteins thought to be 
involved in ATP-dependent drug transport and have been reported to mediate MDR 
[Hayes and Wolf, 1990], via enhancing efflux of chemoprophylactics. Two P-glycoprotein 











Chapter 1 Malaria and ProJ"c;t Background 
homologues of the human mdr-type gene) [Foote et al., 1989; Wilson et aI., 1989]. 
Polymorph isms in pfmdr1 were linked to the CO-resistance phenotype [Foote et aI, 1990]. 
The P-glycoprotein homologue, Pgh 1, is expressed by pfmdr1 and is localized in the food 
vacuole membrane [Cowman et al., 1991] although its expression does not correlate with 
CO resistance [Basco et aI., 1995; Basco et aI., 1996; Wellems et al., 1990; Wilson et al., 
1993]. CO resistance has also been reported to be attributable to mutations in, or 
overexpression of the Pfcrt (P. falciparum chloroquine resistance transporter) gene, which 
codes for an energy-dependent channel or transporter in the food vacuole membrane 
[Fidock et aI, 2000; Sanchez et aI, 2003]. 
Polymorphisms, amplification and overexpression of pfmdr1, seem to correlate with 
mefloquine, quinine and halofantrine resistance [Wilson et al., 1993; Cowman et aI, 1994; 
Foley and Tilley, 1997], as well as sensitivity to CO (strain-specific), artemisinin [Reed et 
aI., 2000] and artesunate [Price et al., 2004]. This suggests that PfPgh-1 (P. falciparum P-
glycoprotein homologue) is involved in conferring resistance to amino alcohol antimalarials 
[Foley and Tilley, 1997], although resistance to the amino alcohols is not reversed by 
verapamil, as one would expect if PfPgh-1 was responsible for resistance, but by a 
neuroleptic [Oduola et al., 1993]. Cross-resistance between the aryl-amino alcohol 
antimalarials [Cowman et aI, 1994] suggests similar mechanisms of resistance to the 
individual drugs within this class [Gay et al., 1990]. The resistance between aryl-amino 
alcohol antimalarials and CO has been shown to have an inverse relationship [Cowman et 
aI., 1994]. 
Resistance Reversal 
Resistance reversal agents or chemosensitizers are agents which increase the sensitivity 
of a resistant strain to a chemoprophylactic to a similar level observed in the sensitive 
strain at sUb-toxic concentrations. Martin et al (1987), demonstrated that verapamil 
(Figure 1.6.2.2.3.), a Caz+ antagonist and established resistance reversal agent in 
neoplastic cells, reversed CO resistance in P. falciparum at sub-inhibitory concentrations. 
This verapamil induced reversal is not stereospecific, and therefore is unlikely to be 
















Figure 1.6.2.2.3.: Structure of verapamil 
Since this discovery, a number of other compounds have been shown to reverse 
resistance in P. falciparum. In general, all of these compounds have similar structures 
consisting of a lipid soluble portion, two planar aromatic rings, a cationic charge and a 
protonatable tertiary nitrogen [Beck, 1990; Rasoanaivo et al., 1996; Zamora et aI., 1988]. 
A number of naturally derived resistance modulator compounds have also been isolated 
from plants prescribed by traditional healers to enhance CQ activity (CQ-adjuvants). An 
example of a plant used as a CQ-adjuvant is Strychnos myrtoides, from which 2 CQ 
potentiating compounds, strychnobrasiline and malagashanine were isolated [Rafatro et 
aI, 2000; Rasoanaivo et al., 1994]. 
1.6.2.3. Artemisinin and its derivatives 
Artemisinin or Qinghaosu was isolated from Artemisia annua, which was used as a 
treatment for fevers and chills. Artemisinin is a sesquiterpene trioxane lactone containing a 
peroxide bridge (Figure 1.6.2.3.1.) [Casteel, 1997; Frederich et al., 2002]. Due to its low 
solubility in water and oil, a number of derivatives were synthesized. The reduction of 
artemisinin yields dihydroartemisinin, from which the first generation analogues 
(ester/ether derivatives), artesunate, artelinate (water soluble), artemether and arteether 
(oil soluble), were synthesized [Meshnick et aI, 1996]. These compounds have short half-
lives and toxicity has been reported [Gordi and Lepist, 2004]. Second-generation 
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R = H Dihydroartemisinin 
R = CHJ Artemether 




R = Artelinale 
---O-COO-Nao 
Fig ure 1.6.2,3,1,: Structure of artemisinin and related first generation analogues, 
Mechanism of action 
Artemisinin and its derivatives are thought to act by forming carbon-centered radicals in 
the presence of iron (Fe 2+). These radicals selectively target and form covalent adducts 
with a number of membranous proteins. This mechanism of action as well as the role of 
the haem iron has recently been disputed [Parapini et aI., 2004], One of the proteins 
targeted by the artemisinins has been identified as PfATP6, a SERCA (sarco/endoplasmic 
reticulum Ca2+-ATPase), It is believed that artemisinins inhibit the activity of PfATP6 
[Eckstein-Ludwig et aI., 2003], 
Artemisinin has also been shown to inhibit the activation of the transcriptional factor NF-
kB, thereby preventing induction of nitric oxide synthase transcription and hence nitric 
oxide synthesis in cytokine-stimulated human astrocytoma T67 cells, High intracerebral 
nitric oxide levels have been proposed to cause neurological disorders in cerebral malaria, 
Artemisinin's potent antimalarial activity could therefore be attributed not only to its ability 
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Structure Activity Relationships 
Figure 1.6.2.3.2.: Assignment of artemisinin's rings. 
SAR studies performed on artemisinin revealed that its complex ring structure is not 
necessary for activity. The D ring (Figure 1.6.2.3.2.) is not required, but ring A is necessary 
for increased activity, probably due to the rigidity it offers the compound The Dring 
oxygen, the trioxane ring and the lactol carbon and oxygen also appear important for 
activity [Casteel, 1997]. The peroxide bridge and available iron were found to be crucial 
[Casteel, 1997; Eckstein-Ludwig et aI., 2003; Meshnick et al., 1996]. The lipophilicity of the 
artemisinins was also shown to be critical to activity, as an increase in polarity, in order to 
increase water solubility, decreases activity [Avery et al., 1993]. 
Resistance 
Resistance to this group of compounds has not yet been reported. It has however been 
shown, that mutations in pfmdr1 (Pgh-1) can influence sensitivity to artemisinins 
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1.7. Strategies to decrease malaria transmission and mortality 
Due to the ever-increasing resistance of malaria parasites to currently available 
antimalarials, there is an urgent need for the development of novel antimalarials as well as 
the rational use of existing ones. 
Education is an inexpensive but powerful tool that can help decrease malaria-related 
mortality. Educating communities about the transmission and symptoms of malaria, ~s well 
as ways to treat it, is vital. The use of vector control, such as bed nets, should be 
encouraged. Trape et al. (2002) noted that by using vector control methods 50% of the 
population living in malaria-infected areas could live in malaria-free areas. Underdosing 
and non-compliance also need to be addressed and communities must be educated about 
responsible drug usage in order to protect against increasing chemoprophylactic 
resistance [McCombie, 1996]. In addition, only drugs that are effective against parasites 
present in the region where the disease was contracted must be used. This will ensure 
optimum treatment and prevent wastage of money on ineffective drug therapy 
[www,who.intltdr/diseases/malaria/diseaseinfo,htmj. 
Alternative drug strategies rnust be developed in order to safeguard the efficacy of 
currently available chernoprophylactics, One such rnethod is through cornpounds that 
modulate resistance, Research into resistance reversal agents, which restore 
chloroquine's efficacy is of great importance due to the drug's selectivity and low cost. 
Another strategy is by applying combination chemotherapy with existing antimalarials in 
order to slow down the rate of resistance development and improve efficacy of the drugs. 
Uganda recently decided to replace chloroquine as its first-line treatment against malaria 
with a combination of sulfadoxine-pyrimethamine and chloroquine, Although chloroquine 
resistance is widespread in this area, the combination is more effective in lowering 
parasitemia and reducing fever than either of the drugs alone, It is thought that drugs, from 
different classes, used in combination with each other may enhance the lifetime of IJsage, 
as the chance of a strain being resistant to both drugs is smaller than that of the individual 











expensive and, although they may work well for the present, it is not possible to predict 
how long they will remain effective [Fidock et ai"~ 2004], 
Research is presently being performed on developing novel antimalarials and resistance 
modulators, except it is very costly, Funding is a huge problem as the most affected 
countries do not have available money to spend on research. Malaria is also a disease that 
has little profit potential as it mainly affects developing countries, Pharmaceutical 
companies are therefore not willing to invest heavily in antimalarial research as there will 
be little to no return, Developments in experimental techniques and advances in 
knowledge, such as the sequencing of the genomes of p, falciparum and Anopheles 
gambiae, offer new tools to aid in research, These advances allow researchers to obtain 
greater insight into vital molecular mechanisms involved in drug and insecticide resistance 
[Carucci, D, 2004; Kanzok and Zheng, 2003], A great deal of research has been put into 
developing vaccines against malaria, and with the help of genomics and proteomics a 
number of vaccines have already entered into the trial phase of development [Moore et ar, 
2002l Unfortunately it will take many years before a vaccine is available for general use 
[Schlagenhauf, 2003l 
As mentioned previously, the control of malaria relies heavily on chemoprophylaxis. Due to 
the rapidly developing resistance of the parasites to currently available antimalarials, new, 
effective antimalarials with novel structures and modes of action need to be developed. 
These compounds must also be highly effective, safe and cheap in order to combat this 
deadly disease In developing nations, 
1.8. Drug discovery 
The first step in the drug discovery process is the identification of a hit compound. A hit 
compound possesses in vitro activity which could be improved via chemical modification. 
Preliminary structure modifications are normally performed on the hit in order to establish 
the molecule'S pharmacophore. Repeated combinatorial chemistry and analogue synthesis 
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1,8,1. Hit discovery 
A hit is normally selected on the basis of its in vitro activity and novel structure, Hits are 
generally new chemical entities (NCE's), NCE's are compounds with novel structures, 
which have been synthesized via combinatorial chemistry or isolated from a novel source, 
such as a natural product. Potential hit compounds are screened against a relevant and 
validated bioassay, These bioassays tend to be performed in vitro, on the causative agent 
of the respective disease, 
There are two main approaches used to discover novel hit compounds; 
Rational approach - This approach is based on the identification of a biological target and 
the design of ligands, which act either as agonists or antagonists, This method uses 
computational chemistry in order to design potential hits, which are then synthesized and 
tested for in vitro activity [Casteel, 1997]. 
Empirical approach - This approach screens a range of compounds derived from 
combinatorial libraries, historical libraries and natural sources, In the past, the focus of this 
approach was the development of large combinatorial libraries, These however, did not 
yield the expected number of NCE's, This was attributed to the scaffold or base structure's 
biological irrelevance, Libraries are now comprised of diverse, drug-like molecules and 
therefore hold more hit potential [Breinbauer et a/" 2002; Teague et a/" 1999]. Natural 
sources offer a great variety of novel compounds on which to base library development. 
Natural products offer great potential as scaffold compounds, as they are biologically 
validated molecules, Most importantly natural products are privileged structures - a class 
of compounds which can bind to various protein receptors [Evans et aI., 1988] and 
therefore libraries based on these compounds will have an enhanced likelihood of yielding 
hit compounds with increased efficacy than libraries based on non-privileged structures 
[Breinbauer et aI., 2002; Brohm et ai"~ 2002], 
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1.8.2. Lead development 
Lead development focuses on developing a compound with selectively potent in vivo 
activity while optimizing absorption and bioavailability. 
Leads can be classified into 3 groups; lead-like leads, high-affinity leads and drug-like 
leads. Table 1.8.1.1. below summarizes their respective properties. 
Table 1.8.1.1.: Lead classification and optimization [Teague et aI., 1999]. 
Lead Affinity (~ M) Molecular weight clogP Optimization 
Lead-like >0.1 <350 <3 Increasing molecular weight and lipophilicity 
Drug-like >0.1 >350 >3 
Reducing molecular 
High-affinity «0.1 »350 <3 weight and increasing 
lipophilicity 
In general lead-like molecules offer the greatest potential for preclinical candidates and the 
selection of leads in this category will decrease optimization needed to be done at later 
stages [Teague et al., 1999]. 
Leads can also be modified uSing methods that predict the biological properties of the 
molecules based on their chemical structures. Methods include identification of 
unattractive functional groups (Le. functional groups renowned for toxicity, metabolic 
lability etc.), prediction of oral bioavailability as well as others [Walters et al., 1999]. An 
example of one such method is Lipinski's 'rule of 5' [Lipinski et al., 1997]. This rule predicts 
that poor absorption and diffusion through membranes and other cellular structures of an 
oral drug is more likely when; 
a) there are more than 5 H-bond donors (sum of OH and NH mOieties) 
b) more than 10 H-bond acceptors (sum of Ns and Os) 
c) the molecular weight is over 500 
d) the clogP is over 5 
A compound that fulfills at least three out of the four criteria adheres to Lipinski's rule. 
This rule has been accepted as defining structural properties which determine a 
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1.9. Project Background 
As mentioned in the previous section, natural sources are invaluable resources of novel, 
biologically validated potential drugs. Medicinal plants provide approximately 80% of the 
world's population with disease treatment [WHO, 1995]. It is generally assumed that a 
plant possessing activity against a certain disease must contain active compound(s) 
responsible for the activity [Phillipson, 2001]. Plants are therefore major sources of 
biologically active pnvileged structures [Caniato and Puricelli, 2003], and many of the 
drugs used today are plant-derived [Farnsworth, 1984]. Of particular interest to this 
dissertation are antimalarial compounds which were isolated from plants, such as quinine 
and artemisinin (see section 1.6.2.). Plant-derived compounds possessing antimalarial 
activity tend to be secondary metabolites such as quinines, terpenes and alkaloids 
[Caniato and Puricelli, 2003]. 
Plants selected for investigation are chosen by random selection, chemotaxonomy or 
ethnopharmacological information [Br0gger Christensen and Kharazmi, 2001]. 
Harpagophytum procumbens, commonly known as Devil's Claw, is indigenous to Southern 
Africa and is traditionally used to treat a number of ailments including fevers and blood 
diseases. It was therefore chosen on an ethnopharmacological basis as a plant with 
potential antiplasmodial activity. Petroleum ether extracts of this plant possessed 
antiplasmodial activity, and further purification and isolation yielded compounds 1 and 2 
(Figure 1.9.1.). Both compounds 1 and 2 were found to possess significant selective 
antiplasmodial activity, and due to their common novel structures were used as hits for 
further structure activity relationship (SAR) studies. The low yields at which 1 and 2 were 
isolated prompted the identification of totarol, a commercially available analogue, for 











Chapter ;' Mala"" ,lI1rf "'''lee! flac~grnund 
OH OH 
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Figure 1.9.1.: Compounds 1 and 2 isolated from Harpagophytum procumbens and totarol 
(3) [Clarkson et al., 2003a]. 
The first set of derivatives synthesized were a range of ~-amino alcohol derivatives (Figure 
1.9.2.). The ~-amino alcohol moiety is a common structural feature in a number of 
antimalarials, such as quinine and mefloquine (see Figure 1.6.2.2.1.) where it forms part of 
a pharmacophore consisting of an aromatic and an amino alc hol moiety separated by 2-3 
carbon atoms. It was thought that combining the privileged naturally derived hit totarol with 
a potentially active amino alcohol moiety would yield derivatives with improved 
antiplasmodial activity. 
Comparison of the results obtained show that all the derivatives synthesized showed 
improved activity, and in some cases improved selectivity, against the intraerythrocytic 



















Totarol (3) is a commercially available compound, and a number of methods describing its 
synthesis have been reported [Bendall and Cambie, 1995]. It is also a naturally occurring 
phenolic diterpenoid, which has been found in a number of plants [Bendall and Cambie, 
1995]. It was first isolated in 1910 from Podocarpus lolara [Bendall el a/., 1994], and was 
the first compound to be discovered with the chemical formula of C2oH300. Totarol was 
named as such as it was believed to possess a tertiary alcoholic group due to the slow rate 
at which it underwent acetylation. Its structure (Figure 1.10.1.) was first identified by Short 
and Wang (1951). 
12 OH 
20 \ 1 ?' 
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Figure 1.10.1.: Structure of Totarol [Short and Wang, 1951]. 
Totarol's chemical name is totara-8, 11, 13-trien-13-01 and its nomenclature is based on the 
parent compound totarane [Bendall el al., 1 994J. The phenol group is sterically hindered by 
the isopropyl group, as determined by the IR spectrum and this accounts for totarol's slow 
rate of acetylation. Steric shielding is present which prevents intermolecular hydrogen 
bonding [Short and Wang, 1951] and thus decreases totarol's apparent polarity [Bendall el 
aI., 1994]. The positioning of substituents, such as the attachment of the isopropyl group 
on C-14, results in totarol's unique chemistry. 
Totarol and derivatives were shown to possess antibacterial activity against Gram-positive 
bacteria only [Evans el a/., 1999; 2000]. This may be due to these lipophilic compounds 
being trapped in the cell membrane lipids of Gram-negative bacteria [Lien el al., 1968], 
which contain a greater percentage of lipids. Derivatives with modifications at rings A and 












derivatives were found to have greater antibacterial activity than that of their parent 
compound totarol [Evans et at, 2000], Structure-activity relationship studies performed on 
totarol, have demonstrated that the phenolic moiety at C-13 is essential for its antibacterial 
activity [Evans and Furneaux, 2000], (+)-Totarol has also been reported to be active 
against Mycobacterium tuberculosis [Constantine et at, 2001], It has been suggested that 
totarol's site of action may be the cell membrane [Haraguchi et at, 1996], or that these 
lipophilic phenolic compounds (totarol and derivatives) may act either by interfering with 
cell wall biosynthesis or by interfering with oxidative phosphorylation via the uncoupling 
effect The uncoupling effect disables ATP synthesis by preventing the formation of the 
electrochemical potential difference across the cell membrane, The uncoupling effect of 
totarol was investigated, but it was found that it was unlikely to be responsible for the 
compounds' antibacterial activity [Evans et at, 2000], 
Totarol has also been found to protect against oxidative stress and has also been shown 
to exert hypercholesterolemic activity in rats, It is thought that totarol acts by inhibiting 
cholesterol absorption from the intestine as well as stimulating cholesterol breakdown 
and/or excretion [Enomoto et a/., 1977]. 
1.11. Project Focus 
The focus of this project is to synthesize and identify possible bioactiphore(s)' of the 
antimalarial hit compound totarol. Hit and lead development tools, as discussed above, are 
therefore extremely relevant at this stage of research in order to maximize both the results 
and value of the research . 
• A bioactiphore is the minimum structural requirement a molecule must contain in order to exhibit in vitro or 
in vivo activity. In the case of a pharmacophore, the receptor(s) is known and therefore the moieties needed 
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2.1. Project Objective 
The overall objective of this project is to develop promising potential antiplasmodial lead 
compounds through chemical modification and SAR (structure-activity relationship) studies 
of a range of totarol derivatives. 
2.2. Specific Aims 
1. Synthesize a number of totarol derivatives and analogues using traditional medicinal 
chemistry techniques. 
2. Characterization of derivatives using analytical and spectroscopic techniques including: 
- Polarimetry 
- Melting point 
Elemental analysis / HPLC 
Mass spectrometry 
I nfrared spectroscopy (I R) 
- Nuclear Magnetic Resonance (NMR) - 1H, 13C, 20 (COSY, HMBC, HSQC) 
3. Evaluation of the in vitro antiplasmodial activity of the derivatives against a chloroquine 
sensitive (010) strain of P. fa/ciparum. 
4. Evaluation of the in vitro antiplasmodial activity of the derivatives, showing activity 
greater than that of totarol in the 010 strain, in a chloroquine resistant K1 strain of P. 
fa/ciparum. 
5. Cytotoxic evaluation of the most active derivatives ustng a mammalian Chinese 
Hamster Ovarian (CHO) cell line. 
6. Investigation into the ability of structurally promising derivatives to reverse chloroquine 
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7. Evaluation of selected analogues' and derivatives' effect on erythrocytic invasion in a 
chloroquine sensitive (010) strain of P. fa/ciparum. 
2.3. Chemical modifications on totarol 
2.3.1. Summary of target compounds 
The following totarol derivatives and analogues (Figure 2.3.1.1.), except phenolic 





































Figure 2.3.1.1.: Parent compounds, totarol (3), phenol (10), 1-naphthol (13) and 2-naphthol 
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2.3.2. Rationale for synthesis of target compounds 




e.g. phenyl and 
naphthol groups 
Nature of side chain 
(e.g. addition of second protonatable 
nitrogen) 
Secondary and tertiary 
amino groups 
Figure 2.3.2.1.1.: Summary of modifications 
Nature of the B-amino group 
This study is aimed at exploring the effect of substitution on the p-amino group by 
comparing secondary and tertiary p-amino substitution. In this regard a secondary p-amino 
alcohol 7 and a tertiary p-amino alcohols 5 and 6 will be synthesized. The addition of a 
second protonatable nitrogen such as in 5 is predicted to increase the compound's 
passage across the cell membrane and accumulation in the parasites acidic food vacuole 
via pH trapping. Compounds which are weakly basic are likely to become trapped in acidic 
compartments due to the existing transmembrane proton gradients. The unprotonated 
base form of the compound readily crosses the membrane into the acidic compartment 
where it is protonated. This protonated form cannot leave the acidic compartment as it 
cannot cross the membrane. pH trapping is thought to account in part for the high levels of 
chloroquine which accumulates in the acidic food vacuole of the malaria parasite [Yayon et 
al., 1984]. The activity displayed by 5 will be compared with the activity reported for a 
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Substitution of totarol backbone 
Substitution of the totarol diterpenoid-like hydrophobic backbone will allow conclusions to 
be drawn about its role in the activity displayed by the totarol derivatives. The totarol 
backbone will be replaced by simple aromatic groups such as phenyl and naphthyl. 
Resistance reversal ability 
In gene~al, compounds which act to reverse chloroquine resistance have similar structural 
features, such as; lipid solubility, two planar aromatic rings, a cationic charge and a tertiary 
nitrogen [Beck, 1990; Zamora et al., 1988]. Totarol derivatives with similar features will be 
tested for resistance reversal ability. 
Effect and comparison of compounds 9 and 18 on erythrocytic invasion 
Haldar et al., (2003) proposed that erythrocytic G protein-coupled receptor signaling, 
invo'lJing the ~2-adrenergic receptor, may be necessary for parasitic invasion of the 
erythrocyte. They demonstrated that ~-blockers (~-adrenergic receptor antagonists) inhibit 
in vitro P. falciparum infection of erythrocytes and decrease parasitaemia in vivo in mice 
infeoted with Plasmodium berghei. 
~-Blockers are commonly used to treat hypertension and tend to possess at least 1 
aromatic ring structure which is attached to an alkyl side chain possessing a secondary 
hydroxyl and amine moiety, as well as one or more chiral centers. At least one of the chiral 
ceniars in the alkyl side chain is directly attached to the hydroxyl group [Mehvar and 
Brocks, 2001]. 
Race:nic propranolol (~-blocker) was shown by Haldar et al., (2003) to inhibit infection, 
although the antagonistic behaviour was stereospecific, as demonstrated by the (+) 
inactive enantiomer. It will therefore be synthesized in racemic form (18) and its effect on 
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3.1. General mechanisms 



































(R = a, b, c, d) 
12 
(R = a) 
15,16,17,18 
(R = a, c, d) 9H R 
CC)"" O~~, I R /- /-
21, 22 
(R = a, c) 
Figure 3.1.1 : Scheme showing a summary of ~-amino alcohol synthesis. 
The starting materials (totarol, 3, phenol, 10, i-naphthol, 13 and 2-napthol, 19) were 
dissolved in DMF, deprotonated by sodium hydride (NaH) and alkylated with 
epichlorohydrin, resulting in the formation of the epoxide intermediates (4, 11, 14 and 20). 
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where a catalytic amount of potassium phthalimide and DMF (solvent) were used, and an 
excess of the amine was added, resulting in the formation of the respective ~-amino 
alcohol derivatives with percentage yields in the range of 29-93% [Lawrence and Bushell, 
2001; Williams et al., 1985]. 
Epoxide intermediate formation 
Figure 3.1.1. below depicts the mechanism by which the epoxide intermediates 4,11,14 
and 20 are formed. In the presence of the strong base, NaH, totarol is converted to a 
phenoxide anion. There are three electrophilic carbons in epichlorohydrin (carbons 1', 2' 
and 3') at which this anion could potentially attack (Figure 3.1.1.). The regiochemistry of 
the reaction is however markedly solvent-dependant. The use of an aprotic solvent, such 
as DMF, favours the reaction shown in scheme A, in which the carbon-halide bond is most 
likely to be attacked by the phenoxide nucleophile. In an alcoholic solvent, hydrogen 
bonding weakens the carbon-oxygen bond favouring attack at carbon 3' rather than carbon 
2' on steric grounds. An intramolecular SN2 reaction then occurs, resulting in displacement 
of CI and formation of epoxides i and ii (scheme B). In the presence of an acid, the oxygen 
of the epoxide is protonated or complexed to a Lewis acid and attack at carbon 2' is 
favoured in order to stabilize the developing secondary positive charge (scheme C) 
[Cruickshank and Fishman, 1969]. As DMF was used as a solvent (aprotic), nucleophilic 
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formation of one diastereomer for the epoxide intermediate and as such for the ~-amino 
alcohol products. 
3.2. Spectroscopic Indicators and Analyses 
Only key spectroscopic signals from lH NMR will be discussed, as it is the key method 
used to evaluate target compounds. Selected spectra are shown in appendix 3. 
The resonances are described as they appear (chapter 4). Possible explanations are given 
below. It should be noted however, that resonances may appear as other multiplets other 
than those expected due to small coupling constants and poor resolution (e.g. a double 
doublet with small coupling constants may appear as a triplet). 






Complete lH and BC data has been reported for totarol lYing and Kubo, 1991]. lH, BC, 
COSY, HMBC and HSQC experiments were performed to confirm the identity of the 
compound and to aid in the lH and BC assignment of the derivatives. 
The hydroxyl group was identified at 8 4.42 using a 020 wash. The H-11 proton (87.00) 
resonates as a doublet (J = 8.8). H-11 was found to couple with a doublet (8 6.51, J = 8.8) 
in the COSY spectrum, which was identified as H-12. The mesomeric effect of the hydroxyl 
group at H-13 causes H-12 to resonate upfield to H-11. Coupling of H-15 (sextet at 8 3.30) 
to two doublets (integrating for 3 protons) identtfied H-16 and H-17 (COSY). The methyl 











Chapter 3 SynthesIs and Charactenz~ tlon of T" t",ol Derivatives and Analogues 
coupling with H-1 ~ and H-2~, at a 0 of 1.17-1.24. H-1 a does not couple with H-2a as the 
two protons are orthogonal to each other. The coupling of H-1 ~ with H-1a (geminal) results 
in the splitting of the signal into a broad doublet. H-1 ~ is also orthogonal to H-2a and H-2~ 
and therefore does not couple to these protons. H-2a and H-2~ couple with 2 neighboring 
fortuitously equivalent hydrogens, resulting in splitting of both signals into double triplets. 
H-3a forms a multiplet by coupling to H-2~ and H-3~. It does not couple to H-2a, as the 
two are orthogonal. H-3~ couples to H-2a (vicinal) and H-3a (geminal) resulting in a broad 
doublet. H-5 is orthogonal to H-6a, but couples with H-6~ and its signal appears as a 
multiplet. Coupling of H-6a with H-6~ and H-7a splits its signal into a double doublet. H-6~ 
is visible as a multiplet between 0 1.55 -1.70. H-7a is also a multiplet, coupling with H-6a 
and H-7~. H-6~ and 7a are orthogonal, and therefore do not couple with each other H-7~ 
couples with H-6~ and 7a, resulting in the formation of a double doublet. HSQC also linked 
H-7a and H-7~ to the same carbon (C-7). The methyl groups at positions 18, 19 and 20 all 
appear as singlets (with an integration of 3), as they do not have neighboring protons with 
which to couple. 
HMBC and HSQC were used to aid in the assignment of the peaks in the 13C spectrum. 
Phenol, 10 
'U:'",: OH I ' . ~, 
Hydrogens at positions 2 and 6 are chemically equivalent and the most shielded due to 
their ortho positioning with respect to the hydroxyl group. These two protons therefore 
appear the furthest upfield and resonate as double doublets. H-4 appears as a triple triplet 
due to large, ortho couplings with H-3 and H-5 and smaller meta couplings with H-2 and H-
6. H-3 and H-5 also resonate as a triple triplet, and are most deshielded therefore 
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1-Naphthol, 13 
OH 
Assignments were established based on the literature as well as resonance structures. H-2 
will resonate as a double doublet, as it is ortho coupled to H-3 and meta coupled to H-4. H-
4 is a triplet due to coupling with H-2 and H-3. H-5 is a doublet due to coupling with H-6. H-
7 and H-8 are multiplets. H-7 appears as a multiplet due to through space deshielding due 
to the hydroxyl group at C-1. H-3 and H-6 are multiplets, although H-6 is the most 





Assignments were established ba ed on the literature as well as resonance structures. 
H-4 and H-6 are the most deshielded due to ring resonance. They therefore appear 
furthest downfield and couple to two chemically equivalent neighbours, H-5 (ortho) and H-7 
(para) and H-5 and H-7 (ortho) respectively. H-3 and H-8 resonate as doublets due to 
coupling with H-2. Protons at positions 5 and 7 resonate as double triplets due to coupling 
with protons in the same ring. H-2 is the most shielded, and therefore resonates furthest 
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Intermediates: Compounds 4, 11, 14 and 20 
o~ 
1




4' ....... 6 
19 18 
Compound 4: H-21a and b were both present as triplets due to geminal and vicinal 
coupling (H-22). These two protons are diastereotopic and therefore interchangeable. H-22 
couples with H-21 a, H-21 band H-23a resulting in a quintet. H-22 and H-23P are 
orthogonal and therefore do not couple. The protons at position 23 are diastereotopic and 
hence both are seen as double double doublets due to coupling with H-23 (a or P) and H-
22. 
. ...••• ~ 
. o~ 
'(Y' . ·V2 , 
11 
Compound 11: H-7a and b appear as double doublets, due to coupling with each other and 
with H-8. H-8 and H-9a appear as a multiplet. H-9P couples with H-9a and H-8 and 
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Compounds 14 and 20: H-9a and band H-11 a and p appear as double doublets, due to 
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9 11 12 
O~Nln , ~,OH 15~N" 
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15 21 
Compounds 15 and 21: Protons at C-13 and C-14 are chemically equivalent and appear 
as a broad singlet upfield to H-12 and H-15, as they are further away from the hydroxyl 
moiety and are therefore more shielded. Protons H-12 and H-15 are chemically equivalent 
and appear as a broad singlets in 15 and 21. 
Compound 7, 16 and 22: 
" 







Compound 7: H-21a and ~ are interchangeable and both are visible as double doublets 
due to geminal and vicinal (H-22) coupling. H-22 appears as a multiplet. H-23 appears as 
a multiplet, due to coupling with H-22. H-24, NH and OH appear as singlets. Protons at 
positions 26-30 all have similar chemical shifts and therefore appear as a multiplet in the 
region 7.26-7.37. 
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Compounds 16 and 22: All protons appeared at similar chemical shifts to those seen in 
compound 7. Their multiplicities were not constant, although this is probably due to inter-
molecule variation and chemical nature 
Compounds 9 and 18: 
OH 
12 O~~ 25 
13 21 22 23 ~ 
'6 1-
2 14 26 
15 
3 
4' ___ , 6 
19 16 
Compound 9: H-22 is the most deshielded out of all the hydrogens in the side chain. H-21 a 
and b each couple with three neighbours (each other, H-22 and H-23a or b). H-24 has 
been deSignated as a broad singlet although, the peak has slight splittings on either side. It 
does couple with H-25 and H-26, as these protons do appear as doublets. 
13 
9 " 1 
~~o 1'0 ~ 14 
, OH , 
6 
5 
Compound 18: The NH and OH moieties were apparent due to their chemical shifts and 
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and b both appear as double doublets due to geminal and vicinal coupling. H-12 appears 
as a multiplet due to coupling with H-13 and H-14. H-13 and H-14 are chemically 




H-10 appears as a quintet, due to equal splitting by four neighbours (a and b protons of H-
9 and H-11). 
Chlorophenyl moiety: H-18 is the most deshielded, because of the inductive effect of the 
CI, and appears as a doublet due to coupling with H-19. H-20 is para to C-17 and is 
therefore also fairly deshielded. It appears as a double doublet, due to unequal couplings 
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H-26 and H-29 are chemically equivalent and the most deshielded protons due to their 
position in an aromatic ring and proximity to the carbonyl groups. They appear as double 
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equivalent and relatively shielded, due to their meta positions. They appear as double 
doublets due to ortho and meta coupling with H-26 and H-29. 
Mass spectra and elemental analysis/HPLC indicated the target amino alcohols were 
correct and pure respectively. Compounds' calculated molecular weights are shown in 
appendix 1 for comparative purposes. All amino alcohols also displayed an OH band at 




















Chapter 4 Materials and Methods 
4.1. General 
Totarol was purchased from Sigma-Aldrich, South Africa, 1- and 2- naphthol from Merck 
and Judex respectively and epichlorohydrin was purchased from British Drug House 
(BOH). The remaining chemicals were obtained from Sigma-Aldrich, South Africa. All 
reactions were monitored via TLC , which was carried out on Merck silica 60 F254 coated 
aluminium sheets. Preparative TLC was performed on Merck silica 60 F254 coated plates 
and column chromatography was performed on Merck Kieselgel silica gel 60. Micro 
(elemental) analysis on all target compounds, except compounds 6, 7 and 17, was 
performed on a Fisons EA 1108 CHNS-O instrument. Purity of compounds 6, 7 and 17 
was confirmed via HPLC on a Waters 996 HPLC and photodiode array detector. The 
HPLC spectra were run on a C18 column with an acetonitrile/water gradient at 
wavelengths ranging between 190-400nm. IR spectra of all compounds, except 7 (1 mg/ml 
solution in OCM), were recorded using KBr disks on a Thermo Mattson FTIR spectrometer 
in the range of 4000-500 cm·1. Low resolution mass spectra (LREIMS) of compounds 4, 6-
8 were obtained on an VG micromass 16 F spectrometer at 70eV while those for 
compounds 5, 9, 12, 15-18, 21 and 22 were obtained on an Applied Biosystems API 2000. 
1H, 13C, COSY, HSQC and HMBC NMR spectra were recorded on Varian 300 MHz or 400 
MHz instruments with TMS as a reference. Chemical shifts are reported in parts per million 
and coupling constants in hertz (Hz). 
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Starting compounds 3,10,13 and 19 
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1H NMR liH (400 MHz; CDCI3) 7.00 (d, J = 8.8, H-11), 6.51 (d, J = 8.8, H-12), 4.42 (s, OH), 
3.30 (sept, J = 7.2, H-15), 2.94 (dd, J = 17, 6.2, H-7~), 2.75 (m, H-7a), 2.23 (br d, J = 11.6, 
H-1~), 1.92 (dd, J = 7.7,1.6, H-6a), 1.73 (dt, J = 13.7, 3.3, H-2~), 1.55-1.70 (m, H-6~), 
1.49 (dt, J = 13.2, 3.2, H-2a), 1.47 (br d, J = 13.2, H-3~), 1.36 (d, J = 7.1, H-17), 1.34 (d, J 
= 7.1, H-16), 118 (s, H-20), 1.17-1.30 (m, H-1a, , H-3a, H-5), 0.95 (s, H-18), 0.92 (s, H-
19). 13C NMR lie (100.6 MHz; CDCI3) 152.0 (C-13), 131.0 (C-14), 123.0 (C-11), 114.3 (C-
12),49.6 (C-5), 41.6 (C-3), 39.6 (C-1), 37.7 (C-10), 33.3 (C-4), 33.2 (C-18), 28.7 (C-7), 
27.1 (C-15), 25.4 (C-20), 21.6 (C-19), 20.3 (C-16, C-17), 19.5 (C-2),19.4 (C-6). 
Optical rotation of totarol 
The angle of rotation was measured on a Perkin-Elmer 141 Polarimeter. 
The optical rotation of a compound is calculated via the following formula [Clayden et aI., 
2001]: 
where D indicates the wavelength of 589nm, 











Chapter 4: Materials and Methods 
ex is the observed angle of rotation (measured 3 times and averaged), 
c is the concentration (g/ml) and 
/ is the path length (dm). 
In th is case; 
a=+0.0415 
c = 0.001g/ml 
/=0.89dm 






1H NMR liH (400 MHz; CDCI3) 7.25 (tt, 7.5,1.8, H-3, H-5), 6.94 (tt, J = 7.8,1.3, H-4), 6.82-
6.86 (dd, J = 7.8,1.2, H-2, H-6), 4.85 (s, OH). 13C NMR lie (100.6 MHz; CDCI3) 155.5 (C-
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1-Naphthol,13 
OH 
1H NMR DH (400 MHz; CDCI3) 8.20 (m, H-6), 7.83 (m, H-3), 7.50 (m, H-7, H-8), 7,46 (d, J = 
8,4, H-5), 7,32 (t, J = 7.6, H-4), 6.82 (dd, J = 7.6, 1.2, H-2). BC NMR DC (100.6 MHz; 
CDCI3) 151.6 (C-1), 135.0 (C-4a), 127.9 (C-5), 126,7 (C-6), 126.0 (C-7), 125,5 (C-3), 124.6 






1H NMR DH (400 MHz; CDCI3) 7.76 (t, J = 8.0, H-4, H-6), 7.67 (d, J = 8,4, H-3), 7,43 (dt, J = 
8.0,1.3, H-7), 7.33 (dt, J = 7,6,1.2, H-5), 7.15 (d, J = 2,4, H-8), 7.10 (dd, J = 8.8, 2,4, H-2). 
BC NMR DC (100.6 MHz; CDCI3) 153.3 (C-1), 134.6 (C-7a), 129.8 (C-3), 129.0 (C-3a), 
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General Experimental Protocol for Synthesis of B-amino alcohols 
Synthesis of epoxide intermediates 4, 11, 14 and 20 
General Procedure 
Sodium hydride (1.5 eq.) was added to a solution of the respective starting compounds 3, 
10,13 or 19 (1 eq.) in DMF at O°C under nitrogen. The reaction mixture was raised to 25°C 
(or 50°C in the case of phenyl epoxide formation) and epichlorohydrin (5 eq.) was added 
dropwise over 2 minutes. The reactions were complete after 12 hours as confirmed via 
TLC. The mixture was diluted with water (100ml), extracted with EtOAc (3 X 100ml) and 
dried over MgS04 Excess epichlorohydrin and EtOAc was removed in vacuo to yield an oil 
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11.1 g (3.88 mmol) of totarol (3), 0.14g (5.82 mmol) NaH and 1.52 (19.41 mmol) 
epichlorohydrin used, resulting oil purified via silica gel chromatography, eluting with 
EhO/Hex (112), Rf = 0.56, giving an isolated yield of 84% (1.12 g). 1H NMR OH (400 MHz; 
CDCI3) 7.07 (d, J = 8.8, H-11), 6.67 (d, J = 8.8, H-12), 4.16 (t, J= 10.9, 3.0, H-21a), 4.14 (t, 
J = 10.9, 3.0, H-21b), 3.98 (ddd, J = 10.8, 5.2,2.4, H-23a), 3.95 (ddd, J = 10.8, 5.2,2.4, H-
23S), 3.36 (m, H-22), 3.3 (sept, J = 7.2, H-15), 2.95 (dd, J= 16.9, 6.0, H-7S), 2.75 (m, H-
7a), 2.24 (br d, J= 11.6, H-1 B), 1.91 (dd, J = 7.9, 1.9, H-6a), 1.73 (dt, J = 13.4, 3.9, H-2S), 
1.55 - 1.72 (m, H-6S), 1.49 (dt, J = 13.2, 3.2, H-2a), 1.47 (br d, J = 13.2, H-3S), 1.36 (d, J 
= 7.1, H-17), 1.34 (d, J = 7.1, H-16), 1.18 (s, H-20), 1.16-1.30 (m, H-1a, H-3a, H-5), 0.95 
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122.7 (C-11), 110.1 (C-12), 68.7 (C-21), 50.3 (C-22), 49.5 (C-5), 44.7 (C-23), 41.5 (C-3), 
39.6 (C-1), 37.7 (C-10), 33.1 (C-4), 33.0 (C-18), 28.7 (C-7), 27.5 (C-15), 25.1 (C-20), 21.5 
(C-19), 24,4 (C-16, C-17), 19,4 (C-2),19.3 (C-6). 
Compound 11: 




Reaction was performed at 50'C. 1.07g (11.39 mmol) of phenol (10), 0.82 (34.17 mmol) 
NaH and 4,45ml (56.95 mmol) epichlorohydrin used, resulting oil purified via silica gel 
chromatography, eluting with EtOAc/Hex (1: 12), Rf =0,48, giving an isolated yield of 88% 
(1.50 g). 1H NMR liH (400 MHz; CDCI3) 4.21 (dd, J = 14.8, 4,4, H-7a), 3.98 (dd, J = 11.1, 
5,4, H-7b), 3.33-3.38 (m, H-8), 2.90 (m, H-9a), 2.75 (dd, J = 5.1, 3.3, H-9P) 13C NMR lic 
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1.02g (7.08 mmol) of 1-naphthol (13), 0.25g (10.5 mmol) NaH and 2.74ml (35 mmol) of 
epichlorohydrin used, resulting oil purified via silica gel chromatography, eluting with 
Et20/Hex (37), Rf = 0,40, giving an isolated yield of 76% (1.08 g). 1H NMR liH (400 MHz; 
CDCb) 4,40 (dd, J = 11.2, 3.2, H-9a), 4.17 (dd, J = 11.0, 5.4, H-9b), 3,48-3.51 (m, H-10), 
2.97 (dd, J = 5.0, 4.2, H-11a), 2.85 (dd, J = 5.0, 2.6, H-11P). 13C NMR lie (100.6 MHz; 
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0.5g (3,47 mmol) of 2-naphthol (1 ,0.1 (5.2 mmol) NaH and 1,35ml (17.3 mmol) of 
epichlorohydrin used, resulting oil purified silica gel chromatography, eluting with 
Et20/Hex (3:7), = 0.51, giving an isolated yield of 92% (632.6 mg). lH NMR OH (400 
MHz; COCh) (dd, J = 11.0, , H-9a), 4.09 (dd, J = 10.8, 5.6, H-9b), 3,42 (m, H-10), 
94 (dd, J = 4 4.0, 1a), 81 (dd, J = 5.2, 1B) DC NMR Oc (100.6 M 
COCI3) 68.8 (C-9), 50.1 (C-10), (C-11). 
re 7,(8),118, 
The respective amine (1.1 eq.) was added to 1 eq. of the respective epoxide in MeOH (1 ml 
per 0.06 mmol starting material). The mixture was stirred 51 cC, for 1 hours, until the 
reaction was complete (verified via TLC), The excess solvent was removed under reduced 
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1 01.3mg (0.30 mmol) of totarol epoxide (4) used, 0.036ml (0.33 mmol) N-methylpiperazine 
used, resulting oil purified using preparative TLC, DCM/MeOH (9:1), R, = 0.56, giving an 
isolated yield of 29% (38 mg). IR Vmax (KBr)/em'
1 3134 (OH), 2805-2938 (CH aliphatic), 
1590 (C=C aromatic); 1 H NMR bH (400 MHz; CDCI3) 7.00 (d, J = 8.8, H-11), 6.51 (d, J = 
8.8, H-12), 4.11 (m, H-22), 3.98 (dd, J = 12.4, 6.4, H-21a), 3.91 (dd, J = 12.4, 6.8, H-21b), 
3.30 (sept, J = 7.2, H-15), 2.94 (dd, J = 17.0, 6.2, H-7~), 2.75 (m, H-7a), 2.57-2.60 (m, H-
23), 2.34-2.56 (m, H-24, H-25, H-26, H-27), 2.30 (s, H-28), 2.23 (br d, J= 11.6, H-1 ~), 1.92 
(dd, J = 7.7,1.6, H-6a), 1.73 (dt, J = 13.7, 3.3, H-2~), 1.55 -1.70 (m, H-6~), 1.49 (dt, J = 
13.2,3.2, H-2a), 1.47 (brd, J = 13.2, H-3~), 1.36 (d, J = 7.1, H-17), 1.34 (d, J = 7.1, H-16), 
1.18 (s, H-20), 1.17-1.24 (m, H-1a, H-3a, H-5), 0.95 (s, H-18), 0.92 (s, H-19). 13C NMR be 
(100.6 MHz; CDCI3 ) 155.1 (C-13), 143.3 (C-9), 133.7 (C-8), 133.2 (C-14), 122.7 (C-11), 
109.8 (C-12), 80.0 (C-21), 70.1 (C-22), 65.9 (C-23), 65.7 (C-24), 61.0 (C-28), 55.1 (C-25), 
53.2 (C-26), 49.5 (C-5), 45.9 (C-3), 41.5 (C-1), 39.6 (C-10), 37.6 (C-4), 33.1 (C-18), 28.7 
(C-7), 27.4 (C-15), 22.9 (C-20), 21.5 (C-19), 20.6 (C-16, C-17), 19.4 (C-2), 19.3 (C-6), 17.0 
(C-28); APCI mlz 443.5 (M+1(, Found: C, 76.0; H, 10.0; N, 6.2. C28H4sN202 requires C, 
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76.8mg (0.22 mmol) of totarol epoxide (4) used, 0.027ml (0.25 mmol) benzylamine used, 
resulting oil purified via silica gel chromatography, eluting with DCM/MeOH (9:1), Rr = 
0.55, giving an isolated yield of 30.5% (30.5 mg). IR Vmax (KBr)/cm,1 3687 (OH), 2953 (CH 
aliphatic), 1603, 1453 (C=C), 707 (C-N); 1H NMR IiH (400 MHz; CDCI3) 7.26-7.37 (m, H-26, 
H-27, H-28, H-29, H-30), 7.00 (d, J = 8.8, H-11), 6.51 (d, J = 8.8, H-12), 4.16 (m, H-22), 
4.00 (dd, J = 9.5,54, H-21a), 3.92 (dd, J = 9.5, 54, H-21b), 3.50 (5, H-24), 3.28 (br 5, H-
15),2.94 (m, H-7~), 2.75 (m, H-7a), 2.96-3.00 (m, H-23), 2.23 (br d, J= 11.6, H-1~), 1.92 
(dd, J = 13.2, 7.6, H-6a), 1.73 (dt, J = 13.7, 3.3, H-2~), 1.55 - 1.70 (m, H-6~), 147 (dt, J = 
13.2,3.2, H-2a), 147 (br d, J = 13.2, H-3~), 1.36 (d, J = 3.6, H-17), 1.34 (d, J = 1.34, H-
16), 1.19 (5, H-20), 1.20-1.39 (m, H-1 a, H-3a, H-5), 0.96 (5, H-18), 0.93 (5, H-19). 13C 
NMR lie (100.6 MHz; CDCb) 155.0 (C-13), 143.5 (C-9), 138.5 (C-25), 133.8 (C-8), 133.1 
(C-14), 1284 (C26, C-27, C-28, C-29, C-30), 122.8 (C-11), 115.5 (C-12), 80.0 (C-21), 70.1 
(C-22), 534 (C-23), 51.3 (C-24), 49.5 (C-5), 41.5 (C-3), 39.6 (C-1), 37.6 (C-10), 33.2 (C-4), 
33.1 (C-18), 28.7 (C-7), 27.3 (C-15), 25.1 (C-16, C-17), 21.5 (C-20), 20.7 (C-19), 194 (C-


















Resulted from prolonged exposure of the epoxide (4) with MeOH. IR Vmax (KBr)/cm'1 3687 
(OH), 2948 (C-H aliphatic), 1604, 1453 (C=C aromatic), 1117 (C-O); 1H NMR DH (400 MHz; 
CDCI3) 7.00 (d, J = 8.8, H-11), 6.51 (d, J = 8.8, H-12), 4.06-4.16 (m, H-22), 4.0 (dd, J = 
12.8,7.0, H-21a), 3.53-3.64 (m, H-23), 3.9 (dd, J = 12.8, 7.0, H-21b), 3.39 (s, H-24), 3.3 
(sept, J = 7.2, H-15), 2.94 (dd, J = 17.0, 6.2, H-7~), 2.75 (m, H-7a), 2.23 (br d, J = 12.1, H-
1~), 1.92 (dd, J = 7.7,1.6, H-6a), 1.73 (dt, J = 13.7, 3.3, H-2~), 1.55 -170 (m, H-6~), 1.49 
(dt, J = 13.2, 3.2, H-2a), 1.47 (br d, J = 13.2, H-3~), 1.36 (d, J = 7.1, H-17), 1.34 (d, J = 
7.1, H-16), 1.18 (s, H-20), 1.17-1.29 (m, H-1a, H-3a, H-5), 0.96 (s, H-18), 0.94 (s, H-19). 
13C NMR Dc (100.6 MHz; CDCI3) 143.5 (C-9), 133.1 (C-8), 122.8 (C-11), 109.9 (C-12), 73.8 
(C-21), 68.7 (C-23), 69.2 (C-22), 59.2 (C-24), 49.5 (C-5), 41.5 (C-3), 39.6 (C-1), 37.6 (C-
10),33.2 (C-4), 33.1 (C-18), 29.6 (C-7), 28.7 (C-15), 25.1 (C-20), 21.5 (C-19), 20.7 (C-16, 
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Compound 9: 
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Reaction was performed at 31°C. 229.9mg (0.67 mmol) of totarol epoxide (4) used, 3 eq. 
(0.3ml, 3.52 mmol) isopropylamine used, resulting oil purified via silica gel 
chromatography, eluting with DCM/MeOH (9: 1), Rr = 0.37, giving an isolated yield of 70% 
(189.3 mg). IR Vmax (KBr)/cm"1 3313 (OH, H bonded), 2960, 2867 (C-H aliphatic), 1590 
(C=C aromatic); 1H NMR liH (400 MHz; CDCI3) 7.09 (d, J = 8.8, H-11), 6.72 (d, J = 8.8, H-
12),4.11 (m, H-22), 3.96 (2 X ddd, J = 9.4,5.1,1.8, H-21a and b), 3.30 (br s, H-15), 2.84-
3.00 (m, H-7~), 2.76-3.00 (m, H-7a, H-23), 2.74 (br s, H-24), 2.25 (d, J = 12.4, H-1~), 1.92 
(dd, J = 13.3, 8.1, H-6a), 1.74 (dt, J = 13.6, 3.3, H-2~), 1.63 -1.72 (m, H-6~), 1.59 (dt, J = 
13.6,3.4, H-2a), 1.47 (br d, J = 14.0, H-3~), 1.20-1.39 (m, H-1a, H-3a, H-5, H-16, H-17), 
1.19 (s, H-20), 1.13 (d, J = 6.4, H-25, H-26), 0.95 (s, H-18), 0.93 (s, H-19). 13C NMR lie 
(100.6 MHz; CDCI3) 155.1 (C-13), 143.5 (C-9), 133.8 (C-8), 133.2 (C-14), 122.8 (C-11), 
110.0 (C-12), 70.2 (C-21), 69.6 (C-22), 49.61 (C-23), 49.59 (C-24), 49.5 (C-5), 49.1 (C-24), 
41.6 (C-3), 39.6 (C-1), 37.7 (C-10), 33.2 (C-4), 33.2 (C-18), 28.7 (C-7), 27.4 (C-15), 25.1 
(C-16), 22.7 (C-17), 21.6 (C-25), 20.7 (C-26), 20.7 (C-20, C-19), 19.5 (C-2), 19.4 (C-6); 
APCI mlz 402.5 (M+Y. Found: C, 77.3; H, 10.2; N, 3.2. C26H43N02 requires C, 77.8; H, 
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500mg (3.61 mmol) of phenyl epoxide (11) used, 0.44ml (3.97 mmol) N-methylpiperazine 
used, resulting oil purified via silica gel chromatography, eluting with DCM/MeOH (9:1), R, 
= 0.43, giving an isolated yield of 67% (608.3 mg). IR Vmax (KBr)/cm-1 3348 (OH H-
bonded), 2938, 2806 (C-H aliphatic), 1596 (C=C aromatic). 1H NMR &H (400 MHz; CDCI3) 
405-4.13 (m, H-8), 3.98 (d, J = 5.1, H-7), 2.73 (br d, J = 5.4, H-9), 2.59-2.51 (m, H-10, H-
11, H-12, H-13), 2.31 (s, H-14). 13C NMR &e (100.6 MHz; CDCI3) 70.2 (C-8), 65.6 (C-7), 
60.5 (C-9), 55.1 (C-10, C-13), 53.1 (C-11, C-12), 45.9 (C-14); APCI mlz 251.2 (M+1f 





190mg (0.95 mmol) of 1-naphthyl epoxide (14) used, 0.12ml (1.1 mmol) N-
methyl piperazine used, resulting oil purified via silica gel chromatography, eluting with 
MeOH , R, = 0.26. The compound was further purified via recrystallization with hexane and 
dried under high vacuum giving an isolated yield of 68% (192.3 mg). IR Vmax (KBr)/cm-
1 
3162 (OH), 3058 (C-H aromatic), 2964-2923, 2878-2782 (C-H aliphatic), 1578 (C=C 
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2.67-2.69 (m, H-11a and b), 2.76 (br s, H-12, H-15), 2.50 (br s, H-13, H-14), 2.31 (s, H-16). 
BC NMR lie (100.6 MHz; CDCI3 ) 70.6 (C-9), 65.7 (C-10), 60.8 (C-11), 55.2 (C-12, C-15), 
53.3 (C-13, C-14), 46.0 (C-16). APCI m/z 301.1 (M+Y Found: C, 70.2; H, 7,7; N, 90. 
C1BH24N202.0.5H20 requires C, 69.9; H, 7.8; N, 9.1. Mp 66-77°C. 
Compound 16: 
9 11 12 14 
6 o~~l015 





0.89 mmol of i-naphthyl epoxide (14) used, 1.1 mmol benzylamine used, resulting oil 
purified via silica gel chromatography, eluting with EtOAc/Hex (1:1), Rr = 0.63, giving an 
isolated yield of 34% (93.4 mg). IR Vmax (KBr)/cm·
1 3279 (OH H-bonded), 3050 (C-H 
aromatic), 2942 (C-H aliphatic), 1580 (C=C aromatic). lH NMR liH (400 MHz; CDCI3) 7.26-
7.51 (m, H-3, H-4, H-6, H-7, H-14 to 18),4.29 (m, H-10), 4.10-4.21 (m, H-9a and b), 3.93 
(d, J = 4, H-12), 292-306 (m, H-11a and b), 2.88 (NH). BC NMR lic (100.6 MHz; CDCb) 
138.4 (C-13), 128.6 (C-15, C-17), 128.5 (C-14, C-18), 127.5 (C-16), 70.5 (C-10), 68.1 (C-
9), 53.5 (C-12), 51.2 (C-11). APCI m/z 308.4 (M+1( Found: C, 78.1; H, 6.6; N, 4.6. 
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Compound 17: 
6 
Neutralization of 1-(2-chlorophenyl)-piperazine monohydrochloride (271 mg, 2.40 mmol) 
with MP-carbonate (3.65mg, 9.6 mmol) in MeOH (7ml) at 20°C for 7 hours yielded amine. 
134.4mg (0.67 mmol) of 1-naphthyl epoxide (14) used. Resulting oil purified via silica gel 
chromatography, eluting with EtOAc/Hex (1: 1), Rf = 0.72, giving an isolated yield of 55% 
(147 mg). IR Vmax (KBr)/cm·
1 3345 (OH H-bonded), 3054 (C-H aromatic), 2807-2933 (C-H 
aliphatic), 1579 (C=C aromatic). 1H NMR bH (400 MHz; CDCI3) 7.26 (d, J = 0.9, H-18), 7.24 
(m, H-20), 7.21 (dd, J = 8.1,1.8, H-21), 7.02 (td, J = 7.6,1.6, H-19), 4.35 (quintet, J = 8.6, 
H-10), 4.15-4.28 (m, H·9a and b), 3.16 (m, H-12, H-15), 2.752-2.819 (m, H-13, H-14), 
2.94-3.00 (m, H-11a and b). 13C NMR be (100.6 MHz; CDCI3) 149.0 (C-16), 130.7 (C-18), 
128.8 (C-17), 125.6 (C-20), 123.9 (C-21), 121.9 (C-19), 70.5 (C-10), 65.6 (C-9), 61.1 (C-
12, C-15), 53.6 (C-13, C-14), 51.1 (C-11). APCI m/z 397.3 (M+ 1)+. HPLC indicated that the 
compound was pure. Mp 107-11rC. 
Compound 18: 
13 
9 11 I 
~~o 110 ~ 14 
1 OH 




Reaction was performed at 31°C. 167mg (0.83 mmol) of 1-naphthyl epoxide (14) used, 3 
eq. (0.30ml, 3.52 mmol) isopropylamine used, resulting oil purified via silica gel 
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IR Vmax (KBr)/cm,1 3271 (OH, H-bonded), 3054 (C-H aromatic), 2963, 2923, 2834 (C-H 
aliphatic), 1583 (C=C aromatic). 1H NMR bH (400 MHz; CDCI3) 4.13-4.21 (m, H-10, OH), 
3.90 (m, H-9a), 3.62 (dd, J = 11.2,3.2, H-9b), 3.39 (dd, J = 11.0, 7.8, H-11a), 3.01 (dd, J = 
16,4.8, H-11b), 2.88 (m, H-12), 2.20 (NH), 1.11 (d, J = 3.1, H-13, H-14). DC NMR be 
(100.6 MHz; CDCI3) 70.7 (C-10), 68.5 (C-9), 68.0 (C-11), 49.0 (C-12), 23.0 (C-13), 22.9 
(C-14). APCI mlz 260.3 (m+Y. Found: C, 71.7; H, 7.9; N, 4.9. C16H21N02.0.5H20 requires 





313.7mg (1.57 mmol) of 2-naphthol epoxide (20) used, 0.19ml (172 mmol) N-
methylpiperazine used, resulting oil purified via silica gel chromatography, eluting with 
MeOH, Rr = 0.18. The compound was further purified via recrystallization with hexane and 
EtOAc and dried under high vacuum giving an isolated yield of 48% (226.2 mg). IR Vmax 
(KBr)/cm,1 3365 (OH), 3025 (C-H aromatic), 2942, 2807 (C-H aliphatic), 1631-1600 (C=C 
aromatic). 1H NMR bH (400 MHz; CDCb) 4.16 (m, H-10), 4.10 (d, J = 3, H-9a and b), 2.73 
(br d, J = 5.7, H-12, H-15), 2.63-2.59 (m, H-11a and b), 2.50 (s, H-13, H-14), 2.31 (s, H-
16). DC NMR be (100.6 MHz; CDCI3) 70.4 (C-10), 65.6 (C-9), 60.5 (C-12, C-15) 55.1 (C-
11, C-15), 53.1 (C-13, C-14), 45.9 (C-16). APCI mlz 301.3 (M+1)+. Found: C, 68.6; H, 7.2; 
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225.7mg (1.13 mmol) of 2-naphthol epoxide (20) used, 0.135ml (1.24 mmol) benzylamine 
used, resulting oil purified via silica gel chromatography, eluting with MeOH, Rr = 0.47, 
giving an isolated yield of 67% (230.7 mg). IR V max (KBr)/cm-
1 3266 (OH H-bonded), 3053 
(C-H aromatic), 2716-2899 (C-H aliphatic), 1601-1629 (C=C aromatic). 1H NMR OH (400 
MHz; CDCb) 7.44 (dt, J = 10.2, 1.6, H-14, H-18) 7.13-7.36 (m, H-2, H-5, H-6, H-8, H-15, H-
16, H-17), 4.19 (m, H-10), 4.10 (d, J = 6.4, H-9a and b), 3.89 (br s, H-12a and b), 2.84-
3.00 (m, H-11a, band NH). 13C NMR 8c (100.6 MHz; CDCI3) 128.5 (C-14, C-18), 128.3 (C-
15, C-17), 127.3 (C-16), 70.4 (C-10), 68.2 (C-9), 53.6 (C-12) 51.1 (C-11). APCI m/z 308.4 
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Compound 4 (294.3 mg, 0.86 mmol), potassium phthalimide (7.7 mg, 0.04 mmol) and 
phthalimide (142,2 mg, 0.946 mmol) were dissolved in DMF (13 ml). The reaction mixture 
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(310), Rr = 0.15. The reaction mixture was diluted with water (50 ml) and extracted with 
CHCb (3 X 50 ml). The extracts were washed with water (2 X 50 ml) and brine (2 X 50 ml) 
and dried over MgS04 . The solvent was removed under reduced pressure to give a 
yellowish oil. The oil was dissolved in EtOAc (100 ml), washed with water (3 X 100 ml), 
dried and loaded onto a silica gel column. The column was eluted with Et20/Hex (310) 
and once the spot of interest had been eluted, baseline material was washed out with 
Et20/Hex (1:1). Fractions were concentrated under reduced pressure and dried on high 
vacuum, resulting in 0.25g (63%) of compound 6. IR Vmax (KBr)/cm-
1 3417 (OH), 2930 (CH 
aliphatic), 1702 (C=O), 1443 (C=C aromatic), 1263 (C-O), 1073 (C-N); 1H NMR &H (400 
MHz; CDCI3 ) 7.88 (dd, J = 5.6, 3.0, H-26, H-29), 7.73 (dd, J = 5,4, 3.2, H-27, H-28) 7.00 (d, 
J = 8.9, H-11), 6.51 (d, J = 8.9, H-12), 4.32 (m, H-22), 4.03 (m, H-21, H-23), 3.34 (sept, J = 
7.2, H-15), 2.94 (dd, J = 17.2, 6.2, H-7~), 2.75 (m, H-7a), 2.25 (br d, J = 11.2, H-1 ~), 1.92 
(dd, J = 7.7,1.6, H-6a), 1.73 (dt, J = 17.0, 3,4, H-2~), 1.55 - 1.70 (m, H-6~), 1,47 (dt, J = 
13.2,3.2, H-2a), 1,47 (br d, J = 13.2, H-3~), 1.35 (dd, J = 10.1, 3.6, H-16, H-17), 1.18 (s, 
H-20), 1.18-1.26 (m, H-1a, , H-3a, H-5), 0.95 (s, H-18), 0.92 (s, H-19). 13C NMR oc (100.6 
MHz; CDCI3) 168.7 (C-24, C-31), 154.9 (C-25, C-30), 143.8 (C-13), 134.1 (C-26, C-29), 
133,4 (C-27, C-28), 132.0 (C-14), 123.5 (C-11), 122.9 (C-12), 109.9 (C-22), 69.6 (C-21), 
69.3 (C-5), 49.5 (C-3), 41.6 (C-23), 41.5 (C-1), 39.6 (C-10), 37.7 (C-4), 33.3 (C-18), 33.2 
(C-7), 29.7 (C-15), 28.8 (C-16), 25.2 (C-17), 21.6 (C-20), 20.9 (C-19), 19.5 (C-2), 19,4 (C-
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4.2. Antiplasmodial activity and Cytotoxicity testing 
4.2.1. Determination of in vitro antiplasmodial activity 
4.2.1.1. Culturing of Plasmodium falciparum parasites 
Strains were cultured according to methods described by Trager and Jensen (1976). The 
chloroquine sensitive clone, D10 (originated from FCQ-27 from Papua New Guinea) 
[Ekong et al., 1993], and chloroquine resistant strain, K1 (Kanchnaburi, Thailand) 
[Thaitong et al., 1981]. were maintained at a 4% hematocrit in RPM I 1640 (Biowhittaker) 
medium supplemented with Albumax II (GIBCOllnvitrogen), HEPES, gentamicin and 
sodium bicarbonate (Sigma). The medium was changed daily. The parasitaemia was kept 
below 10% with erythrocy1es obtained from 0+ blood (Western Province Blood Transfusion 
Service, Groote Schuur Hospital, Cape Town, South Africa). Medium without Albumax II 
was used to wash the blood in order to obtain packed erythrocy1es. The parasites were 
synchronized when in the ring stage with sorbitol, as described by Lambros and 
Vanderberg (1979). The cultures were maintained in flat blottomed 75 cm 3 flasks in an 
atmosphere of 93% N2, 4% CO2 and 3% O2 at 37°C. 
4.2.1.2. Experiment and plate setup 
Chloroquine control: A 10mg/ml stock solution of CQ (Sigma) was made up and serially 
diluted to 2 fLg/ml with medium, which was loaded onto the plate. 
Compounds: The compounds were dissolved in either methanol (MeOH) or 
dimethylsulfoxide (DMSO) (Table 4.2.1.2.1.) and made up to a 1 mg/ml stock solution with 
Millipore water. The solvent and the ratio in which it was used was chosen according to 
each compound's solubility. Controls were prepared using the various solvents at the 
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Table 4.2.1.2.1.: The various solvent ratios in which compounds 3-22 were dissolved. 
Compound Solvent Ratio of solvent to 
water 
3 MeOH 1:4 
4 MeOH 1:4 
5 MeOH 1 :9 
6 DMSO 1:4 
7 DMSO 1:4 
8 DMSO 1:4 
9 MeOH 1:4 
10 MeOH 1:4 
11 MeOH 1:4 
12 MeOH 1 :9 
13 MeOH 1:4 
14 DMSO 1:4 
15 MeOH 1 :9 
16 MeOH 1:4 
17 MeOH 1:4 
18 MeOH 1:4 
19 MeOH 1:4 
20 DMSO 1:4 
21 MeOH 1 :9 
22 MeOH 1:4 
The stock solutions were sonicated thoroughly before water was added to ensure the 
compounds had fully dissolved and that the solutions were sterile. It was found that if the 
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precipitate. All solutions were stored at 20°C, and new solutions were made up every 
couple of weeks. 
All compounds were initially tested for in vitro antiplasmodial activity on the chloroquine 
sensitive (010) strain of P. fa/ciparum. Compounds showing activity greater than that of 
totarol (compounds 5-9, 16, 22) were then tested on a chloroquine resistant (K1) strain. 
Compounds 12, 15, 18 and 21 were tested for comparative purposes. The selectivity of 
compounds showing activity greater than that of totarol in the K1 strain (compounds 5, 7-9, 
15, 16, 18, 21 and 22) were tested for cytotoxicity. Compound 12 was tested for 
comparative purposes. 
The experiment was performed in 96 well microtitre plates. These plates contain 96 wells, 
which are arranged in 12 columns (1-12) and 8 rows (A-H). 2001-11 of the chloroquine 
control was loaded into the first two wells of column 3 (i.e. 3A and 38). 2001-11 of the 
respective compounds, diluted to the appropriate concentration in medium, were loaded in 
duplicate in the remaining wells of column 3. 1001-11 of medium was added to all wells 
except those in column 3. Using a multichannel pipette, 1001-11 of the drug solution was 
removed from every well in column 3 and added to column 4 and mixed. These series of 
dilutions continue until the end of the plate. 100 1-11 of parasitised red blood cells (2% 
hematocrit and 2% parasitaemia) was then added to each well in columns 2-12. This 
halves the concentration of the compound; the highest concentration of compound to 
which the parasites were exposed is 100l-1g/ml and the highest concentration of 
chloroquine was 11-1g/ml. 1001-11 of non-parasitised red blood cells (2% hematocrit) are 
added to the wells in column 1 (blank). The total volume in each well is 2001-11. The plate is 
then gassed and incubated at 37°C for 48 hours. Column 1 serves as a blank and contains 
only red blood cells at a final hematocrit of 1 %. Column 2 contains no drugs, while 
columns 3 to 12 contain parasites and a range of drug concentrations. The experiment is 
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4.2.1.3. Parasite lactate dehydrogenase assay 
The lactate dehydrogenase assay differentiates between live and dead parasites by 
measuring the activity of the parasite lactate dehydrogenase enzyme (pLOH). pLOH 
activity is differentiable from the erythrocyte lactate dehydrogenase (LOH) activity as it 
uses an analog of nicotinamide adenine dinucleotide (NAO+), called 3-acetyl pyridine 
adenine dinucleotide (APAO+) much faster than LOH does. This results in the production of 
APAOH which reduces nitroblue tetrazolium producing formazan crystals from which the 
amount of live parasites is then determined spectrophotometrically [Makler ef aI., 1993]. 
100).\1 of Malstat reagent (triton X-100, 1mg/ml, APAO, 0.33g/L, TRIS buffer, 33g/L in 
millipore water and lactate) is transferred to all wells in a new microtitre plate. All wells in 
the incubated plate are resuspended, and 15).\1 of the various 'solutions' from each column 
are then transferred into the plate containing 100).\1 of Malstat reagent. 25).\1 of a solution 
containing nitroblue tetrazolium, 1.96 mM (Sigma) and phenazine ethosulfate, 0.24 mM 
(Sigma) in millipore water was added and the absorbance of the formazan salt is read by a 
7520 Microplate Reader (Cambridge Technology) t 620nm. 
4.2_1.4. Data analysis 
The % parasite viability was calculated using the formula below: 
% parasite viability = Absorbance test well (columns 3-12) X 100 
Absorbance of the positive control (column 2) 
The results were analyzed using Microsoft Excel 2000 and Prism 4.0. 
The resistance index [RI = IC50 (K1)/IC5o (010)] for compounds tested against both 010 
and K1 strains was determined. The RI gives an indication of the difference in activity of 
the various compounds in a sensitive and resistant strain of P. falciparum and is used as a 
factor to evaluate whether novel antimalarials have potential activity against CO resistant 
parasites_ 
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4.2.2. Determination of cytotoxicity 
4.2.2.1. Chinese Hamster Ovarian cell culture 
Chinese ovarian cells were maintained in culture and medium was changed daily. The 
medium consisted of Dulbecco's Modified Eagles' Medium (DMEM): Hams (1 :1) (Sigma) 
supplemented with heat inactivated fetal calf serum (FCS) (10%) and gentamicin (0.04 
Ilg/ml), which were all purchased from Highveld Biological, South Africa. The cells were 
maintained in 75cm3 flasks in a 5% CO2 humidified atmosphere at 37°C. Subculturing was 
performed once the cells were confluent. A 0.25% trypsin solution was used for 
subculturing and cells only underwent a maximum of 10 subcultures. 
4.2.2.2. Experiment and plate setup 
Emetine control: The 2mg/ml stock solution was diluted in medium until a concentration of 
2ng/ml was obtained. 
Compounds: Only those compounds showing improved activity when compared to totarol 
against both the 010 and K1 strains of P. fa/ciparum were tested. The 1 mg/ml stock 
solutions were diluted with complete medium to a concentration of 200 Ilg/ml. This was 
then further diluted in a series of 10 fold dilutions to a lowest concentration of 0.002 Ilg/ml. 
Experiments were performed using a cell concentration of 105 cells/ml. 
Culture plates (96 well) from Costar were used for the experiment. 100111 of cell 
suspension (mix between each row) and 100111 of medium are added to columns A-G. 
200111 of CM is added to column H (blank). Column G is the positive control. Columns A-F 
will contain the compounds. The plate is then incubated overnight (24 hours). After this 
time period, the plate is checked under the microscope to see if the cells have settled and 
are in the exponential phase. The medium is then removed from the wells via aspiration 
and 100111 of the various concentrations of emetine or compounds is loaded in triplicate. 
100111 of medium is then added to each well so the emetine or compound concentration in 
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100 f-Lg/ml (column F) and the lowest concentration was 0.001 f-Lg/ml (column A). The plate 
is then incubated for 48 hours. 
The experiment was performed on separate occasions in triplicate and repeated until two 
reproducible results were obtained. 
4.2.2.3. MTT assay 
The MTT (3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay measures 
the amount of viable cells indirectly by using the metabolic activity of mitochondria which 
are only present in viable cells. On addition of a yellow water-soluble tetrazolium salt, the 
mitochondria (within viable cells) metabolize this yellow salt into a purple water-insoluble 
formazan product. The amount of purple formazan product produced is proportional to the 
number of active mitochondria and therefore the number of viable cells [Mosmann, 1983]. 
After the 48 hour incubation period, 25f-L1 of MTT (Sigma, 5mg/ml in Millipore water) was 
added to each well. The plate is then incubated for a further 4 hours. On removal of the 
plate, purple crystals will be observed. These are the formazan product and indicate that 
viable cells are present. The plate is then spun at 200 rpm for 10 minutes, after which the 
medium is carefully aspirated off. 100f-L1 of DMSO (dissolves formazan crystals, so the 
absorbency can be read) is added and the plates are shaken for 3-5 minutes to assist in 
the solvation of the crystals. The plates are then read on a Microtitre Plate Reader at 
540nm. 
4.2.2.4. Data analysis 
The % cell viability is calculated as shown below; 
% Cell viability = Absorbance test well (columns F-Al 
Absorbance of positive control (column G) 
X 100 
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The selectivity index [SI = ICso (CHO)/ ICso (01 0/K1 )], gives an indication as to how 
selective compounds are towards P. fa/ciparum, and it was determined for compounds 
tested for cytotoxicity. 
The dose response curves are shown in appendix 2. 
4.3. Effect of compounds 5 and 7 on tritiated chloroquine accumulation 
This experiment is carried out in triplicate. Parasites (in trophozoite stage with a 
parasitemia of 5% and a hematocrit of 1 %) in 1.5ml microcentrifuge tubes are incubated 
for 15 minutes at 37°C in the presence of various concentrations of compounds 5, 7 and 
verapamil (positive control; Sigma) after which eH]CQ (Moravek, USA) was added (final 
concentration 4nM). The solutions are then heated for an hour, shaking them after half an 
hour. 100~tI of dibutylphthalate (OBP) (Sigma) is then added to separate the parasitised 
red blood cells and the unparasitised red blood cells from the rest of the mixture. The 
mixtures are spun for 15 seconds and the supernatant is aspirated off. The microcentrifuge 
tip containing the parasites is cut off and placed in a scintillation vial. 100111 of Solvable 
(Perkin Elmer) is added which digests the pellet 25111 of EOTA (0.1M) is added to disable 
catalase to prevent it from interfering with the peroxide which is used to bleach the mixture. 
100111 of peroxide (30%), followed by 2mls of scintillation fluid (packard Bioscience), is 
added to each tube. The radioactivity within the various mixtures was counted using a 
Packard Tri-Carb 2100TR liquid scintillation spectrophotometer. The experiment IS 
performed on separate occasions until two reproducible results were obtained. 
4.4. Chloroquine potentiating effect of 5 and 7 
The chloroquine potentiating ability of each compound should be determined at a 
concentration which has optimum chloroquine uptake and is non-toxic to the parasite. The 
chloroquine-resistant K1 strain of Pfa/ciparum is used. Plates are setup containing CQ, as 
described in section 4.2.1.2. A calculated amount of the prospective chemosensitizers are 
added to each well, as well as a verapamil control (1 I-lM). The plate is incubated for 48 
hours [Adaptation of Chawira and Warhurst, 1987]. The ICso of the parasites in the 
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dehydrogenase (pLDH) assay [Makler et a/., 1993J as described in section 4.2.1.3 .. The 
experiment is performed in duplicate on separate occasions until three reproducible results 
were obtained. 
4.5. Measurement of erythrocytic lysis 
This is determined indirectly by quantifying the amount of haemoglobin (released when 
cells lyse) in the medium. Dose response experiments of selected compounds were 
performed as described in 4.2.1.2. although only RBC at a hematocrit of 2% were used. 
The plates were incubated for 48 hours, after which the erythrocytes were spun down and 
the supernatant was removed and transferred to a separate 96 well plate. The amount of 
haemoglobin was measured on a Microtitre Plate Reader at 405nm. 
4.6. Erythrocytic morphology effect assay 
Dose response experiments of selected compounds were performed as described in 
4.2.1.2. although only RBC, at a hematocrit of 2% were used. After a 48 hour incubation 
period, the plate was placed on a shaker for approximately 2 minutes. The erythrocytes 
were fixed by adding 100fll of 1 % gluteraldehyde (Sigma) in 3% paraformaldehyde to 
100fll of erythrocyte suspension from each well. The erythrocytes were examined and 
photographed by phase contrast light microscopy at X1000. 
4.7. Invasion assay 
Parasites used were in the schizont stage of development with a hematocrit of 1 % and 
parasitemia of 2%. Parasites were exposed to the selected compounds at their respective 
ICso values until all obvious schizonts had burst and a new ring stage was evident in the 
control culture. Parasite viability was determined via Giemsa stained smears. A minimum 
number of 1000 cells were counted [Haldar et al., 2003]. The experiment was performed 




















Chapter 5 Effect of Incorporation of a ~-Amino Group on the In Vitro Antip lasmod ial Activity and Cytotoxicity 
of Totarol 
5.1. Introduction 
The effect of the incorporation of ~-amino groups with different substitutions and side 
chains will be examined in this section. The ~-amino alcohol portion of the molecule is a 
potent pharmacophore present in quinine and mefJoquine (Figure 1.6.2.2.1.), and it is 
therefore likely that it plays an important role in the observed anti plasmodial activities of 
the synthesized derivatives. 
5.2. Results 
The effect of the ~-amino group on the antiplasmodial activity of totarol was investigated 
and the results are shown below in Table 5.2.1 .. Compounds synthesized for this study are 
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Figure 5.2.1.: Structure summary of totarol (3) and synthesized derivatives 4-9. 
(Note: Although compound 9 was synthesized for investigation into its effect on erythrocyte 
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of Totarol 
ICso's~ol de[ivatives (D10, K1 aDd Cl::jO) 
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Figure 5.2.2.: Summary of totarol (3) and derivatives (4-9) ICso values in D10, K1 and CHO 
(ND = Not determined as activity was not greater than that of totarol). 
In general all derivatives synthesized have activity better than that of totarol in both CO 




A number of (+)-totarol's antibacterial actions are thought to be mediated by its interaction 
with the cell membrane. It has been shown that (+)-totarol incorporates into membranes 
very efficiently, as would be expected due to its hydrophobic character [Mateo et al., 2000; 
Micol et al., 2001], thereby disturbing membrane structure. (+)-Totarol has been shown to 
orientate itself in the phospholipid bilayer with its phenol group facing inwards (i.e. into the 
membrane), thereby disrupting phospholipid packing and interaction [Mateo et al. 2000]. 
Disruption of the membrane may also be a possible mode of action for (+)-totarol and its 
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chloroquine sensitive and resistant strains (compounds 4, 5 and 8). Totarol and its 
derivatives are also lipophilic, as indicated by their clog P values (appendix 2) which are all 
greater than 5, and are therefore likely to target the cell membrane. 
Cytotoxicity experiments indicate that totarol is highly selective [Clarkson et aI., 2003bj. 
This leads to the suggestion that totarol, if it is orientated in the membrane, perhaps binds 




The activity of compound 4 is very similar to that of totarol, although its resistance index is 
slightly higher. It is therefore likely that the mechanism of action of these two compounds is 
similar. The increased activity of compounds 5, 7, 8 and 9 in both strains and 6 in the 010 
strain relative to the activity of compound 4, can therefore be attributed to the compounds' 








Compound 5 was shown to have one of the highest activities out of all the derivatives 
synthesized in both 010 and K1 strains. It is approximately 8 times more effective than 
totarol in both these strains. The structure of compound 5 was designed to contain two 
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acidic food vacuole due to the weak base effect (as seen with chloroquine). Compound 5 
displayed similarly high activity in both sensitive and resistant strains as indicated by the 
resistant index (RI = 1.03). The similarity in ICso values between the chloroquine sensitive 
and resistant strains indicates that the mechanisms by which chloroquine resistance is 
conferred do not affect the accumulation or activity of 5 in the parasite. 
The selectivity index of 5 is very low, indicating that it is a toxic compound with relatively 
low specific antiplasmodial activity. This toxicity may be caused by the basic terminal NMe 
moiety since related compounds with a less basic N-Aryl moieties are significantly less 







Compound 6 is an imide but may also be regarded as a tertiary i3-amino alcohol derivative. 
It has the highest ICso for both strains. The tertiary nitrogen in this compound is unlikely to 
become protonated as its electron pair is not available due to delocalisation of the 
electrons into the adjacent carbonyl groups. Comparison with the other tertiary i3-amino 
alcohols, such as 5-9, leads to the suggestion that a protonatable tertiary nitrogen is 
necessary for activity. Compound 6 also has a RI of 5.06, indicating that this compound is 
more active in the sensitive strain. This may be due to the compound; 
i) Not reaching its target in the resistant strain. 
ii) The target may be altered in the resistant strain. 
The structures of chloroquine and 6 differ considerably and hence it would be unlikely that 
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Compounds 7 and 9 are secondary f3-amino alcohols. They have a R, of 0.1 and are 
therefore much more active in the K1 strain than in the 010 strain. Mefloquine, halofantrine 
and quinine also display a similar pattern of activity as these two compounds in 010 and 
K1 strains, which is opposite to that seen with CO [Cowman et aI., 1994]. Mefloquine 
resistance has been correlated with resistance to other amino-alcohol containing 
antimalarials and linked to an amplification and upregulation of pfmdr1. This suggests that 
the 010 resistance to these amino-alcohol containing compounds may be in part attributed 
to PfPgh-1 (a protein which encoded by pfmdr1 and localized to the food vacuole 
membrane) [Foley and Tilley, 1997], and the analogous lipophilicity of the compounds. 
Compounds 7 and 9 display over 10- and 50-fold higher activity than that of totarol in the 
K1 strain and over 10- and 100-fold higher cytotoxicity respectively. There is therefore a 
significant increase in toxicity which may contribute to the observed increase in 
antiplasmodial activity, although the difference in activity between the 010 and K1 strains 
does suggest some selectivity in the action of compounds 7 and 9. 
Compound 8 
8 
Compound 8 has better activity than that of totarol. It has a resistance index of 1.19, 











Chapter 5 Effect of Incorpo ration of a ~-Amino Group on the In Vitro Antiplasmodial Activity an d Cytotox icity 
of Totarol 
also highly selective (SI = 10). Its IC50 values are fairly high in comparison to the other 
derivatives synthesized and may be due to the absence of a protonatable nitrogen. Due to 
its weaker activity, 8 was not investigated further. 
For comparative purposes, Table 5.3.1. below shows the IC50 values of the tertiary f3-
amino alcohol derivatives of totarol synthesized by Clarkson et al. (2003b). 
Table 5.3. 1. : IC50 values of tertiary f3-amino alcohol totarol derivatives [Clarkson et aI., 
2003b]; RI = IC50 (K1 )IIC5o (D1 0) ; SI = IC50 (CHO)/ IC50 (K1) . 
l' 2' - 7' 
Compound R 
ICso (!lM) RI SI 
D10 K1 CHO 010 K1 
1" - 0.61 0.63 7.73 1.04 12.67 12.21 
~ 2" ~I 1.4 0.9 94.19 0.64 67.28 104.89 N I ~ CI 
3" J8 2.56 1.81 105.44 0.71 41.19 58.13 N 
4" N~ 3.25 0.9 >186 0.23 >57 >207 
CI 
5" N~ 1.62 1.01 >182 0.62 >112 >1.80 
(0 
6" 0 2.07 0.56 5.61 0.27 2.71 10.04 











Chapter 5 Effect of Incorporatio n of a I'I -Amino Group on the I" Vllro Antlplasmodial Activi ty and Cytotoxicity 
of Totarol 
Figure 5.3.1. depicts all the ~-amino alcohol derivatives whose antiplasmodial activities are 





































Figure 5.3.1.: Structure summary of ~-amino alcohol totarol derivatives. 
* Compounds 1-7 synthesized by Clarkson et al. (2003b). 
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c:::::J D1 0 
K1 
Figure 5.3.2.: Comparison of the IC50 values of all the f3-amino alcohol derivatives. 
All f3-amino alcohol derivatives have better activity than that of totarol (except 6 in K1 strain 
- pg 73). The majority of the f3-amino alcohol derivatives have resistant indices that vary 
around 1. The exceptions are 4*, 6*, 7 and 9, all of which are most active in K1, and 6, 
which is more active in D10. Comparison of compounds allows predictions to be made 
about the structure-activity relationships. Comparison of 6* and 7* indicates that 
substitution of the 0 with a CH2 moiety decreases activity in the K1 strain. Another 
possibility is that the mechanisms by which chloroquine resistance is conferred result in 
increased susceptibility to compounds 4*,6*, 7 and 9. 
Compounds 2*-5* and compound 5 have similar structures in that they all possess a 
piperazine moiety forming the amino portion of the f3-amino alcohol. Their IC50 values are 
also comparable and do not vary greatly from sensitive to resistant strains (with the 
exception of 4*). This moiety may therefore play some role in the mode of action of these 
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of Totarol 
- --------------
Compound 1* is has a greater selective antiplasmodial activity than compound 5, 
indicating that a second protonatable nitrogen decreases selectivity. 
Compounds 1*, 6* and 7* all have similar activity in the K1 strain. All of these compounds 
are cytotoxic. Compounds 6* and 7* however, have better activity in the K1 strain 
indicating that there is a level of selectivity towards the parasite. The difference in activity 
in the K1 strain between these compounds and all the other l3-amino alcohol derivatives 
implies that a piperazinyl mOiety may not be necessary for activity, and a bulky side-chain 
attached to the piperazine moiety perhaps reduces the compounds' activity by interfering 
with binding to the target molecule. 










1* 2* 3* 4* 5* 6* 7* 5 6 7 9 
Compound 
Figure 5.3.3.: Comparison of the cytotoxicity of all the l3-amino alcohol derivatives. 
(NO = Not determined as activity was not greater than that of totarol). 
See pg 79 for structures 
Cytotoxicity and selectivity indices of the compounds were generally found to correlate. 
The less basic the atoms in the side chain, particularly the l3-nitrogen, the more selective 
(and less cytotoxic) the compound. The two most selective compounds are 4* and 5*. Both 
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electron pair on the N is therefore delocalized into the aromatic ring and hence not entirely 
available for interactions with other molecules or cellular components. 
Table 5.3.2.: Table showing fold increase in antiplasmodial activity and cytotoxicity of ~­
amino alcohol derivatives with respect to totarol (See pg 79 for structures of compounds). 
Compound Fold increase in Fold increase in 
activity cytotoxicity 
5 8.4 45.7 
7 18 11.8 
8 1.2 1.8 
9 68.8 133.2 
1* 18.5 22.05 
2* 13 1.8 
3* 6.4 1.6 
4' 13 <0.9 
5' 11.6 <0.9 
6' 20.9 30.4 
7* 15.6 57.0 
In general an increase in activity is accompanied by a substantial increase in cytotoxicity, 
except with compounds Band 2*-5*, indicating that the ~-amino alcohol substituent imparts 
toxicity and hence non-selective antiplasmodial activity. Compounds 2*-5* possess tertiary 
electron-poor ~-nitrogen atoms and bulky aromatic side chains indicating that these 
structures may be important in conferring selectivity. Compound B is not a ~-amino alcohol, 
although the fold increase in its antiplasmodial activity and cytotoxicity are similar, 
indicating that the hydroxyl moiety may also playa role in the toxicity. 
5.4. Symmary and Conclysion 
In general, the addition of a ~-amino alcohol side chain greatly increases the cytotoxicity 












Chapter 5 Effect of Incorporation of a p-Amino Group on the In Vitro Antlplasmodial Activity and Cytotoxicity 
of Totarol 
Compounds 5, 7 and 9 displayed the highest antiplasmodial activities out of the 
compounds synthesized in this project. Comparison with compounds 6 and 8 leads to the 
assumption that a protonatable nitrogen is necessary for activity. This activity however, 
does not appear to be selective, as selectivity indices tend to decrease with increaSing 
basicity of the l3-nitrogen. 
Comparison of the derivatives' fold increase in antiplasmodial activity and cytotoxicity 
relative to totarol suggests that an electron-poor nitrogen attached to a bulky aromatic side 





















Chapter 6 Effect of Rep lacing the Totarol Backbone on the !n Vitro Antipiasmodiai Activity and Cytotoxicity 
of Selected Compounds 
6.1. Introduction 
Totarol is an expensive compound, both to purchase and synthesize. It was therefore 
decided to determine whether replacing the totarol backbone would yield analogues with 
similar if not superior selective antiplasmodial activities, as well as determining the role of 
the totarol backbone in the antiplasmodial activitiy. 
6.2. Results 
The totarol backbone of selected derivatives (Figure 6.2.1.) was replaced with simple 
aromatic groups such as, phenOl, 1-naphthol and 2-naphthol (Figure 6.2.2.). Compound 9 
was also compared with its 1-naphthol derivative, 18. The in vitro antiplasmodial activities 













Figure 6.2.1.: Derivatives selected for totarol backbone replacement. 
(Note: Although compound 9 was synthesized for investigation into its effect on erythrocyte 
invasion, it will be discussed with reference to the effect of totarol substitution with 1-
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Chapter 6. Effect of Replacing the Totarol Backbone on the In Vitro Antiplasmod ial Activity and Cytotoxic ity 
of Selected Compoll nds 
Table 6.2.1.: Summary of the IGso values of totarol analogues as well as the calculated RI 
and SI values [RI = IGso (K1)IIGso (010); SI = IGso (GHO)/IGso (K1)]. 
Compound lC50 119/ml (11M) RI 
SI 
D10 K1 CHO 010 K1 
3.38 ± 0.72 3.35 ± 0.22 
48.79 ± 0.96 
3 (Totarol) 
(11.78±2.53) (11.69 ± 0.78) 
(170.46 ± 3.35) 0.99 14.5 14.6 
[Clarkson et a/., 2003] 
10 >100 NO NO - - -
11 11.57±2.91 NO NO 
(77.04 ± 19.38) - - -
12 >100 
15.07 ± 3.53 
>100 >0.2 >1 >6.6 
(60.18 ± 14.10) 
13 
8.15 ± 0.48 NO NO 
(56.51 ± 3.32) 
- - -
14 25.82 ± 1.90 NO NO (128.96 ± 9.49) - - -
15 
12.56 ± 0.59 2.17 ± 0.30 78.51 ± 3.88 
0.17 6.2 36.1 
(41.81 ± 1.97) (7.23 ± 0.98) (261.35 ± 12.92) 
16 
1.59 ± 0.15 0.23 ± 0.01 2.54 ± 0.17 0.14 1.6 11.2 
(5.18 ± 0.48) (0.73 ±0.02) (8.27 ± 0.56) 
17 >100 NO NO - - -
18 9.77±1.14 2.64 ± 1.09 >100 0.27 >2.6 >37.8 
(37.68 ± 4.40) (10.19 ± 4.20) 
19 
16.58 ± 1.98 NO NO 
(115.00 ± 13.73) 
- - -
20 
37.47 ± 6.70 NO NO 
(239.97 ± 42.91) 
- - -
21 
12.90 ± 0.23 2.47 ± 0.84 44.67 ± 2.96 
0.19 3.5 18.1 
(42.94 ± 0.76) (8.21 ±2.79) (148.70 ± 9.84) 
22 
2.08 ± 0.81 4.16 ± 1.32 37.93 ± 6.63 
2.0 18.2 9.1 
(6.77 ± 2.64) (13.53 ± 4.29) (123.40 ± 21.58) 











Chapter 6: Effect of Replacing the Totarol Backbone on the In Vitro Anti plasmodial Activ ity and Cytotoxicity 
of Selected Compounds 
6.3. Discussion 
6.3.1. Phenol substitution 
























Comparison of activities between totaml 
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Figure 6.3.1.2.: Comparison of activities between totarol (3) and phenol (10) as well as 
compounds 5 and 12. 











Chapter 6. Effecl of Replacing the To;arol Backbone on the In Vll ro Antlplasmod.a! Activit y and Cytotox,cJy 
of Selected CompoundS 
As can be seen in Figure 6.3.1.2, the substitution of the totarol backbone with a phenyl 
group completely abolishes activity. 
6 3 2 l-Naphthol substitution 








































Chapter 6 Effect of Replacing the Totarol Backbone on the In Vitro Antiplasmod ial Activity and Cytotoxicity 
of Selected Compounds 
~-------------------------------
40 
Comparison of activities between totarol 
and 1-naphthol substitution 
261.35 
56.51 





Figure 6.3.2.2.: Comparison of activities between totarol (3), 1-naphthol (13), totarol 
derivatives (5,7,4* and 9) and 1-naphthyl analogues (15, 16, 17, 18). 
(ND = Not determined as activity was not greater than that of totarol). 
The privileged compound totarol (3) is again much more active than the simpler aromatic, 
1-naphthol (13). Replacement of the to arol backbone in compounds 5, 4* and 9 drastically 
decreases activity. The behaviour of 9 (i.e. more active in the K1 strain) is however 
conserved in compound 18. On  may therefore attribute this increased activity in K1 to the 
isopropylamine side chain. The activity of compound 5 is similar in both the 010 and K1 
strains, while its analogue, 15 does not display similar behaviour as its activity is far 
greater in the K1 strain. This suggests that the two compounds (5 and 15) have different 
target(s). In the case of 4*, activity was completely abolished at the maximum 
concentration tested, indicating that the totarol backbone is solely responsible for the 
observed activity of 4*. 
Replacement of the totarol scaffold in 7 does not abolish the antiplasmodial activity or 
toxicity. Compound 7 and its 1-naphthyl analogue, 16 have comparable activity, toxicity 
and behaviour (i.e. increased activity in K1). The anti plasmodial activity of compound 16 
relative to all the other 1-naphthyl analogues seems to correlate with its cytotoxicity 











Ch apter 6. Effect of Replacin g the Totaml Backbone on the In VItro Antiplasn10dial Activity and Cytotoxici ty 
of Selected Compounds 
implies that this compound is somewhat selective. Compound 16 is 1.2-, 0.9- and 1.7-
times more active/toxic than 7 in D10, K1 and CHO respectively. Comparison of the 
activity of compounds 7 and 16 indicates that the benzylamine side-chain is responsible for 
the observed toxicity and somewhat selective antiplasmodial activity. Replacement of the 
totarol backbone does however seem to increase toxicity of this compound. 
6.3.3. 2-Naphthol substitution 
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Figure 6.3.2.2.: Comparison of activities between totarol (3), 1-naphthol (19), totarol 
derivatives (5 and 7) and 2-naphthyl analogues (21 and 22). 
(ND = Not determined as activity was not greater than that of totarol). 
Totarol (3) is again much more active than 2-naphthol (19). The replacement of the totarol 
backbone in compound 5 decreases antiplasmodial activity although 21 is much less toxic 
to CHO cells. Compounds 5 and 21 do not display similar behaviour and 21 is much more 
active in K1. The replacement of the totarol scaffold in 7 however does not abolish the 
activity, and compound 7 and its 2-naphthyl analogue, 22 have comparable activity in the 
010 strain. The behaviour evident in compound 7 (i.e. increased activity in K1) is not 
mimicked in 22. The replacement of totarol in 7 decreases the cytotoxicity by a factor of 8. 
6.4. Summary and Conclusion 
In general, totarol derivatives were much more active and cytotoxic than the phenyl, 1-
naphthyl or 2-naphthyl analogues. This was expected as totarol, having been isolated from 
a natural source, is a privileged structure and hence it is more likely to possess biological 
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Figure 7.2.3.: Photographs of erythrocytes exposed to the respective 
compounds at sLtJ-lytic concentrations. 
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Chapter 7 Effect of Totarol and Its Derivatives on Ery th rocyte Morphology and LysIs 
Compounds 5 (6.25IJ.g/ml) and 16 (100IJ.g/ml) caused modification of erythrocytic shape, 
although the morphological changes did not correlate with their respective activities, 
although this is a qualitative study and only gross effects are observed. Detailed analysis 
and observations would therefore have to be performed using electron microscopy. 
7.3. Sum mary 
The effect of potential lead antiplasmodial compounds on erythrocytic lysis and shape is an 
important factor to address when considering if the observed activity is selective and 
indeed truly antiplasmodial. The compounds tested had no effect on erythrocytic lysis and 
morphology at concentrations corresponding to their respective antiplasmodial activities. 
The activity displayed by these compounds is therefore specific for the parasite and not an 
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Chapter 8: Effect of Selected Derivatives on CQ Accumulation and Potentiation 
8.2. Effect of compound 5 on CQ accumulation and potentiation. 
8.2.1. Effect of compound 5 on CQ accumulation 
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Figure B.2.1.1.: The effect of 5 on 3H-CQ accumulation in the CQ resistant K1 strain. 
Table B.2.1.1.: Increase in CQ accumulation caused by compound 5. 
Concentration Fold increase P value Significantly different to 
of 5 over pRBC pRBC accumulation 
control 
10/-lg/ml 2.168 0.0034 Yes 
1 /-lg/ml 3.185 0.0002 Yes 
500 ng/ml 1.808 0.0030 Yes 
250 ng/ml 1.774 0.0145 Yes 
125 ng/ml 2.243 0.0012 Yes 
50 ng/ml 2.119 < 0.0001 Yes 











Chapter 8: Effect of Selected DenvatlVes on CO Accumulation and Potentiation 
A significant increase in chloroquine accumulation was noted within the concentration 
range between 10~g/ml to 10ng/ml. Interestingly, little difference in the accumulation was 
seen in the concentration range of 500ng/ml to 10ng/ml. A 50-fold dilution therefore had 
little effect on chloroquine accumulation. The constant level of the graph may indicate that 
there are a limited number of specific target molecules (e.g. chloroquine or proton influx or 
efflux pumps) to which 5 is binding. At a concentration of 10ng/ml all the proteins are 
bound and therefore a further increase in compound 5 has little effect on accumulation. 
The IC50 value of 5 is 0.67 ~g/ml for the resistant (K1) strain. Above this IC50 value further 
increase in accumulation is observed. This increase may be due to unspecific action as the 
compound is highly toxic at these concentrations. The decrease in accumulation observed 
at 1 O~g/ml is most probably due to lysis of the erythrocyte caused by the high 
concentrations of 5 (chapter 7). 

















-3.0-2.5-2.0-1.5-1.0-0.50.0 0.5 1.0 1.5 2.0 2.5 3.0 
Log [compound 5] (~g/mt) 
IC" = 668.344 ± 153.699 ng/ml 
Figure 8.2.1.2.: Dose response curve of compound 5. 
The largest significant uptake of 3H_CQ was seen at a concentration of 1 ~g/ml of 
compound 5. The resistance reversal assay would therefore ideally be performed at this 
concentration. However, it is clear from the dose response curve (Figure 8.2.1.2.) that at a 
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Chapter 8: Effect of Selected Derivatives on CO Accumulation and Potentiation 
8.3. Effect of compound 7 on CQ accumulation and potentiation. 
8.3.1. Effect of compound 7 on CO accumulation 
Figure 8.3.1.1. shows the effect of compound 7 on 3H-CO accumulation. 
o. 
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Figure 8.3.1.1.: The effect of 7 on 3H-CO accumulation in the CO resistant K1 strain. 
Compound 7 does not increase 3H_CQ accumulation, and therefore does not influence the 
mechanisms by which CO accumulation occurs. This however does not discard the 
possibility that 7 may still possess CO potentiating ability, as it may act synergistically with 











Chapter 8 Effect of Selected Derivatives on CO Accumulation and Potentiation 













Compound 7 (K1) 
-4.0 ·3.5 -3.0 -2.5 ·2.0 -1.5 -1.0 -0.5 0.0 0.5 1.0 1.5 2.0 2.5 3.0 
Log [compound 7] ().lg/ml) 
ICso = 220.293 ± 54.665 ng/ml 
Figure 8.3.2.1.: Dose response curve of compound 7. 
As shown by the dotted line on the above dose response curve of 7 (Figure 8.3.2.1.), the 
concentration at which parasite viability is closest to 100% is 10 ng/ml (log[10ng/mll = -
2.0). The assay was therefore performed at 1 Dng/ml as compound 7 is sub-toxic at this 
concentration. 
Figure 8.3.2.2. below shows the dose response curve of CO alone and in combination with 
compound 7 and Verapamil (control). There is no evident shift in the CO+7 curve when 












Chapter 8 Effect of Selected Derivatives on CO Accumulation and Potentiation 
Compound 7 (10ng/ml) 
O~--~~---P----r---~----.---~ 
-3.0 -2.5 -2.0 -1.5 -1.0 -0.5 0.0 
Log [Cq] (Ilg/ml) 
• CQ + 7 (10 ng/ml) 
.. CO + verapamil (1 IlM) 
• CO 
Figure 8.3.2.2.: Dose response curves of compounds 7 + CQ, Verapamil + CQ and CQ. 
Table 8.3.2.1.: RMls obtained for verapamil and compound 7. 
Compound ICso Compound + CQ (ng/ml) RMI = ICso compound + CQlIC50 CQ 
CQ 158.489 -
Verapamil (1 )lM) 78.343 0.49 
Compound 7 251.189 1.58 (10ng/ml) 
Compound 7 did not increase CQ accumulation and had a RMI of 1.58, indicating that CQ 
and 7 have antagonistic mechanisms of action. 
8.4. Summary and Conclusion 
Compound 5 increases 3H-CQ accumulation while compound 7 does not, although both 

















































Chapter 9 Effect of Selected Compounds on Erythrocytic Invasion 
Graph showing the effect of selected compounds 









Control 18 9 
Compounds 
16 7 
Figure 9.2.2: Effect of selected compounds on erythrocyte invasion. 
Table 9.2.1.: % Parasitaemia's achieved by cultures treated with selected compounds 




relative to control to control 
Control 8.83 ± 1.58 - - -
9 5.43 ± 1.87 61.5 ± 21.2 0.0005 Yes 
18 5.35 ± 1.18 60.6 ± 13.4 <0.0001 Yes 
7 8.31 ± 1.59 94.1 ± 18.0 - No 
16 10.24 ± 2.38 116.0 ± 27.0 - No 
Compound 18 (racemic form of propranolol) and its totarol derivative, 9 caused a decrease 
in parasitaemia relative to the control, while compounds 7 and 16 did not influence the 
pa rasitaemia. 
9.3. SummarY and Conclusion 
It was found that compounds 9 and 18 (propranolol), tested at their respective IC50 values, 
approximately halved the parasitaemia relative to the control culture, while compounds 7 











9: Effect of Selected Compounds on Erythrocytic Invasion 
1 as an 




I Inhibition of invasion may be one of the many effects of 9 and 18, it is as 50% 
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::;; 220.293 ± 54.665 ng/ml 



















[comp,ourld 6] ()lg/ml) 
'0 
-25+--.----r--r---r-~,......;;;.-+--r----. 
-1.0 -0.5 0.0 0.5 1.0 1.5 2.0. 2.5 3.0 .'. 












-3.0 -2.5 -2.0 -1.5 -1.0 -0.5 0.0 0.5 
rcolnDound 9]( 
~n ..... n"''''''15 
-1.0 -0.5 0.0 0.5 1.0 1.5 2.0 2.5 
( 
::: 2.173 ±O.295 
18 
-1.0 -0.5 0.0 0.5 1.0 1.5 2.0 2.5 3.0 
2.642 ± 1.088 
12 
-1.0 -0.5 0.0 0.5 1.0 1.5 2.0 2.5 
:: 1S.066± 3.529 
16 
-1.0 -0.5 0.0 0.5 1.0 1.5 2.0 2.5 
16] 
225,944 ± 5,046 
-0.5 0.0 0.5 1.0 1.5 2.0 2.5 3.0 
21] (J.!Q/ml) 











-1.0 -0.5 0.0 0.5 1.0 2.0 2.5 3.0 
:::: 2.118 ± 0.299 
-4 -3 -2 -1 o 1·' 2 3 -4 -3 -2 -1 1 2 3 
r rn'Tlnn,1I nrl 5] 












4 ~ 4 ~ 0 1 2 3 -4 ..J -2 -1 0 1 2 3 
nnannn 9]( 
::: 0.516 ± 0.206 ::: 78.509 ± 3.881 
Cnl"lnnnllnti 21 
II 
4 ..J -2 -1 0 2 3 4 ..J -2 -1 0 1 2 3 
=2.541 ± 0.172 :: 44.668 ± 2.957 
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Figure A3_1_3_: COSY of Totarol (3) 
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Figure A.3.1.4.: HMBC of Totarol (3) 
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Figure A.3.1.5.: HSQC of Totarol (3) 
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FiqureA3_2_1_: 1H NMR of Compound 4 
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Figure A.3.2.2 .: 13C NMR of Compound 4 
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Figure A3.3.1.: 1 H NMR of Compound 5 
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Figure A.3.3.3. : COSY of Compound 5 
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Figure A.3 .5.2.: 0 20 wash of Compound 7 
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Figure A3.5.3. : 13C NMR of Compound 7 
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Figure A3 .5A.: COSY of Compound 7 
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Figure A.3 .5.5.: IR of Compound 7 
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Figure A.3.6.3.: IR of Compound 8 
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Figure A3.7.3 .: 13C NMR of Compound 9 

































Figure A.3.7.3.: IR of Compound 9 
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Figure A.3.B.4. : IR of Compound 16 
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